



THE DEPENDENCY OF FAITHFUL CELL DIVISION ON 
HYPERPHOSPHORYLATION OF ACUTE MYELOID 
LEUKAEMIA ASSOCIATED CYTOPLASMIC 
NUCLEOPHOSMIN 





A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF 
PHILOSOPHY 
DEPARTMENT OF BIOLOGICAL SCIENCES 







I hereby declare that this thesis is my original work and it has been 
written by me in its entirety. I have duly acknowledged all the 
sources of information which have been used in the thesis. 
 




















Portions of chapters 4 and 5 have been published in the online journal Scientific reports 







The sole candidate’s name on the front page of this thesis is deceptive for, as the saying 
goes, it takes a village. I am but the town crier. 
Firstly, the village chief, A/Prof Lim Tit Meng who spared no effort to make the journey 
smoother, securing the grant money from the Ministry of Education without which this 
work would not be possible. Also, foreign relations liaison, Yan Tie and his innovative 
answers to every problem. 
Secondly, my fellow villagers Ban Xiong, Baidah, Jacqueline, Suzan, Pooi San and Yuen 
May who made the labour not so laborious. Not forgetting my one and only UROPS student 
George who strove on despite being clueless sometimes.  



















TABLE OF CONTENTS 
1 INTRODUCTION ................................................................................................................................ 1 
1.1 NUCLEOPHOSMIN ......................................................................................................................................... 1 
1.2 CELLULAR FUNCTIONS ................................................................................................................................ 3 
1.2.1 Nuclear roles .............................................................................................................................................. 3 
1.2.2 NPM as a shuttling/transport chaperone .................................................................................... 6 
1.2.3 Cytoplasmic roles ..................................................................................................................................... 6 
1.2.4 Lesser known post-translational modifications ........................................................................ 8 
1.3 NPM IN CANCER .......................................................................................................................................... 8 
1.3.1 Oncogenic roles ........................................................................................................................................ 8 
1.3.2 NPM as a tumour suppressor .......................................................................................................... 10 
1.3.3 Haematological cancers .................................................................................................................... 10 
1.4 ACUTE MYELOID LEUKAEMIA.................................................................................................................. 12 
1.5 NPMC .......................................................................................................................................................... 12 
1.5.1 Location, location, location ............................................................................................................. 15 
1.6 MITOSIS ....................................................................................................................................................... 16 
1.6.1 Endoplasmic reticulum and Golgi apparatus.......................................................................... 17 
1.6.2 Endosomes and lysosomes ................................................................................................................ 18 
1.6.3 Mitochondria .......................................................................................................................................... 18 
1.6.4 Nucleoli ..................................................................................................................................................... 18 
1.7 CENTROSOMES ........................................................................................................................................... 19 
1.7.1 Structure and organisation ............................................................................................................. 19 
1.7.2 Duplication .............................................................................................................................................. 20 
1.8 CELL DEATH ................................................................................................................................................ 24 
1.8.1 Extrinsic apoptosis ............................................................................................................................... 25 
1.8.2 Intrinsic (mitochondrial) apoptosis............................................................................................. 26 
1.9 OBJECTIVES ................................................................................................................................................. 28 
2 METHODS AND MATERIALS ...................................................................................................... 29 
2.1 CELL CULTURE ........................................................................................................................................... 29 
2.2 DRUG TREATMENT .................................................................................................................................... 29 
2.3 S100 CELL LYSIS ........................................................................................................................................ 29 
2.4 GST PULLDOWN ......................................................................................................................................... 30 
2.5 TOTAL CELL LYSIS ..................................................................................................................................... 30 
2.6 ELECTROPHORESIS AND WESTERN BLOT ............................................................................................. 31 
2.7 TRANSFECTION .......................................................................................................................................... 32 
2.8 IMMUNOFLUORESCENCE ........................................................................................................................... 32 
2.9 CELL CYCLE ANALYSIS ............................................................................................................................... 33 
2.10 SITE-DIRECTED MUTAGENESIS ................................................................................................................ 33 
2.11 COLOURIMETRIC CASPASE ACTIVITY ASSAY .......................................................................................... 34 
2.12 PHOSPHORYLATED H2A.X ASSAY ........................................................................................................... 34 
2.13 CELL DEATH ASSAY .................................................................................................................................... 34 
2.14 STATISTICS .................................................................................................................................................. 34 
3 XIAP REGULATION AND EXPRESSION IN NPMC EXPRESSING CELLS .......................... 35 
3.1 INTRODUCTION .......................................................................................................................................... 35 
3.1.1 Rationale .................................................................................................................................................. 35 
3.2 RESULTS ...................................................................................................................................................... 37 
3.2.1 NPM binds to Fbw7γ which regulates myc stability ............................................................ 38 
 v 
 
3.2.2 XIAP protein level is inconsistent with mRNA expression and does not decrease 
upon cdk2 inhibition ........................................................................................................................................... 40 
3.2.3 NPMc-expressing cells have greater caspase 3 and 9 activity ........................................ 43 
3.3 DISCUSSION ................................................................................................................................................. 46 
3.3.1 The complexities of XIAP regulation. .......................................................................................... 46 
3.3.2 The non-isogenicity of AML2/3...................................................................................................... 47 
3.3.3 A new direction: The elevation of T199 phosphorylation. ................................................ 49 
4 CAUSES OF INCREASED NPMC PHOSPHORYLATION ......................................................... 51 
4.1 INTRODUCTION .......................................................................................................................................... 51 
4.2 RESULTS ...................................................................................................................................................... 52 
4.2.1 Increased phosphorylation is not dependent on kinase levels, activation or 
localization ............................................................................................................................................................. 52 
4.2.2 NPM phosphorylation is dependant on subcellular localisation .................................... 55 
4.2.3 More NPMc is phosphorylated earlier in the cell cycle than wtNPM ........................... 58 
4.3 DISCUSSION ................................................................................................................................................. 59 
4.3.1 Possible causes of disparate phosphorylation ........................................................................ 60 
4.3.2 CRM inhibitors and NPM ................................................................................................................... 61 
4.3.3 Phosphorylation and centrosomes ............................................................................................... 63 
5 CONSEQUENCES OF INCREASED NPMC PHOSPHORYLATION ........................................ 65 
5.1 INTRODUCTION .......................................................................................................................................... 65 
5.2 RESULTS ...................................................................................................................................................... 66 
5.2.1 Phosphorylation inhibition causes greater G2/M arrest of cells with only one 
centrosome in NPMc-overexpressing cells than wtNPM and GFP counterparts .................... 66 
5.2.2 Serine 4 is also disparately phosphorylated ............................................................................ 69 
5.2.3 Alanine-mutated NPMc mimics G2/M phase arrest caused by cdk2 inhibition ...... 70 
5.2.4 NPMc-expressing AML cell line is more sensitive to dephosphorylation inhibition
 72 
5.3 DISCUSSION ................................................................................................................................................. 75 
5.3.1 NPM and other centrosome regulators ...................................................................................... 77 
6 CONCLUSION ................................................................................................................................... 80 
6.1 LIMITATIONS .............................................................................................................................................. 84 
6.2 FUTURE WORK............................................................................................................................................ 85 
6.2.1 PIP3 signalling ....................................................................................................................................... 85 
6.2.2 Clinical prospects .................................................................................................................................. 86 
6.3 CLOSING REMARKS .................................................................................................................................... 86 







Nucleophosmin (NPM) is a multifunctional protein that is predominantly localised in the 
nucleolus. However, in one-third of acute myeloid leukaemia (AML), a frame-shift 
mutation in the C-terminus abolishes the nucleolar localisation signal causing cytoplasmic 
delocalisation. This mutant, known as NPMc, does not contribute to leukaemogenesis by 
upregulating XIAP and cannot inhibit the intrinsic caspases 3 and 9. Instead, the 
centrosome-related phosphorylation sites threonine 199 and serine 4 are 
hyperphosphorylated on NPMc as compared to wild-type NPM which is of interest as 85% 
of clinical NPMc+AML have a normal karyotype upon which normal centrosome 
duplication is dependant. Levels of kinase and phosphatase do not differ between wtNPM 
and NPMc-expressing cells and phosphorylation decreases upon nuclear relocalisation 
indicating that cytoplasmic localisation is the primary cause of hyperphosphorylation. 
Furthermore, G2/M phase centrosome phosphorylation sites are not differentially 
phosphorylated implying that the breakdown of the nuclear envelope during mitosis 
abolishes the relevancy of NPM’s location to its phosphorylation.  Inhibition of 
phosphorylation leads to accumulation of cells with 4n DNA without a corresponding 
increase in the number of cells with 2 centrosomes, meaning that the DNA and centrosome 
duplication cycles are uncoupled. In conclusion, this work provides evidence that the 
normal karyotype in NPMc+AML is linked to the phosphorylation of NPM’s centrosome-
related sites paving the way for the possibility of targeting NPMc in conjunction with 
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Identified in the late 1970’s as a 37kDa nucleolic protein (Lischwe et al. 1979), 
nucleophosmin (NPM) has since been found to be involved in a plethora of cellular 
processes from ribosome biogenesis (Herrera et al. 1995) to histone chaperoning 
(Gadad et al. 2011). Also known as numatrin or B23 (accession no. NM_002520), this 
294 amino acid protein (Figure 1.1) is the most ubiquitously expressed and well-studied 
member of the nucleophosmin gene's three splice variants which is located on 
human chromosome 5p35 (Falini et al. 2009). The second splice variant 
(NPM1.2/B23.2, accession no. NM_001037738) is expressed at minimal levels and is 
thought to be associated with the cytoskeleton (Wang et al. 1993). It is 259 amino acids 
long and lacks the 35 C-terminal amino acids of the 1st splice variant which contains 
the nucleolar localisation signal (NoLS) necessary for nucleolar localisation. As such 
NPM1.2 is localised to the nucleoplasm instead (Lee et al. 2007). Little is known about 
the third splice variant (NPM1.3/B23.2, accession no. NM_199185).  
Being just outside the size limit for nuclear magnetic resonance (NMR), the structure 
of the whole nucleophosmin molecule is not currently known and only portions of the 
N- and C-terminus have entries in the protein databank (www.pdb.org). 
The N-terminus of NPM (amino acids 1-122) is an eight-stranded β-barrel homo-
oligomerisation domain capable of forming pentamers and decamers (Lee et al. 2007) 
and the majority of cellular NPM is found in multimers (Chan and Chan 1995). The C-
terminal 53 amino acids of NPM, which is essential for its nucleolar localisation 
consists of a 3-helix bundle, joined to the rest of the protein by an unstructured 17-





Figure 1.1 Domain structure of NPM. 







Figure 1.2 The last 50 residues of NPM.  
PDB entry 2VXD. Highlighted are tryptophans 288 and 290 which are essential for the 




1.2 Cellular Functions 
1.2.1 Nuclear roles 
1.2.1.1 Nucleoli and ribosomes 
As NPM was first discovered in the nucleolus, the heart of ribosome production, it is 
no surprise that NPM functions in ribosome synthesis.  Nucleoli structural integrity is 
dependent on NPM S125 phosphorylation by casein kinase 2 (Szebeni et al. 2003). 
Mutation of S125 to non-phosphorylatable alanine leads to reticulated nucleoli and 
decrease rRNA transcription (Louvet et al. 2006). NPM also contains intrinsic 
ribonuclease activity (Savkur and Olson 1998) and knockdown of NPM inhibits pre-
rRNA processing and induces cell death (Itahana et al. 2003). 
During mitosis, the nucleolus breaks down and nucleolic proteins like NPM relocate to 
the perichromosomal layer. Some NPM remains associated with condensed 
chromosomes from metaphase to anaphase and decondensing chromosome in 
telophase. However, most NPM is indiscriminately distributed in the mitotic cell. 
(Hernandez-Verdun and Gautier 1994; Van Hooser et al. 2005). Furthermore, NPM is 
localised to the centre of mitotic spindle poles but does not participate in spindle pole 
formation (Zatsepina et al. 1999). 
1.2.1.2 DNA integrity 
The nucleus contains the majority of genetic information needed for cellular function 
and as a predominantly nuclear protein, NPM plays a role in guarding and protecting 
the fidelity of DNA. During S phase, NPM binds and stabilises DNA polymerase η 
(polη), the loss of which is seen in the hereditary disease xeroderma pigmentosum 
whose increased risk of skin cancer is caused by the lack of polη gene which would 
otherwise prevent DNA double-stranded breaks and genomic instability by repairing 
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DNA lesions. NPM knockdown or depletion of NPM from the nucleus by the mutant 
cytoplasmic NPMc leads to increased proteasomal degradation of polη and decreased 
translesion DNA synthesis (Ziv et al. 2014).  
However translesion synthesis is inherently error prone and NPM also contributes to 
template-dependent base excision repair (BER). NPM stimulates the BER enzyme 
apurinic/apyrimidinic endonuclease 1 (APE1). Knockout or cytoplasmic delocalization 
of NPM results in truncation and accumulation of APE1 in the cytoplasm, respectively, 
increasing sensitivity to genotoxic assaults (Poletto et al. 2014; Vascotto et al. 2014). 
In response to DNA damage, NPM is dephosphorylated by protein phosphatase 1β 
which increases its interaction with the tumour suppressor retinoblastoma protein 
(pRB), reducing its transcription-repressing activity on E2F1. E2F1 is then upregulated 
and can promote the transcription of nucleotide excision repair genes RPA3, XPC and 
DDB2 (Lin et al. 2010).  
NPM also prevents cells with damaged DNA from progressing into mitosis by binding 
to amino acids 61-100 of Gadd45a, maintaining it in the nucleus where it inhibits the 
mitotic kinase complex cdk1-cyclin B. Gadd45a is upregulated in response to DNA 
damage but does not have its own nuclear localization signal and is dependent on NPM 
for nuclear localisation. Knockdown of NPM leads to increase in cytoplasmic Gadd45a 
and reduced G2/M phase cell cycle arrest (Gao et al. 2005). 
Finally, NPM’s C-terminus stimulates DNA polymerase α activity (Umekawa et al. 




1.2.1.3 Transcription factors 
NPM also has a role in regulating guardian of the genome, p53 (Lane 1992), directly 
interacting with its heterodimerization domain (amino acids 186-259). Overexpression 
of NPM relocalises p53 in the nucleolus instead of its usual nucleoplasmic location. 
This increases transcription of p53 response genes hdm2 and p21 and inducing cellular 
senescence and growth inhibition (Colombo et al. 2002).  NPM also directly interacts 
with Hdm2, the negative p53 regulator, preventing it from interacting with p53 and 
thereby stabilising the latter (Kurki et al. 2004).  Downstream of p53, NPM interacts 
with p21, reducing its ubiquitination and degradation and increasing its stability (Xiao 
et al. 2009).  
In addition to p53, NPM can complex with other transcription factors such as NF-κB 
and Sp1, upregulating the expression of the antioxidant protein MnSOD (Dhar et al. 
2004; Xu et al. 2007; Xu et al. 2008).  
NPM also interacts with activating transcription factor 5 (ATF5), promoting its 
proteasome- and caspase-dependant degradation by competing with its interaction with 
HSP70 which stabilises ATF5 (Liu et al. 2012a).  
In embryonic stem (ES) cells, NPM interacts with Oct4, Nanog and Sox2 (in ectoderm 
differentiation) and along with the chaperone protein Tpt1, promotes ES cell 
proliferation (Johansson et al. 2010; Johansson and Simonsson 2010). 
1.2.1.4 Other roles 
NPM itself is also a chaperone, binding to core histones H3, H2B and H4 by its N-
terminus while the C-terminus mediates chromatin unfolding and transcription which 
is dependent on both histone and NPM acetylation (Swaminathan et al. 2005). On the 
other hand, NPM indirectly decreases chromatin accessibility by binding to high 
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mobility group A (HMGA), preventing it from modifying DNA and recruiting 
transcription factors (Arnoldo et al. 2015). Finally, NPM acts as a phosphatidylinositol 
3,4,5-triphosphate receptor, preventing apoptosis by inhibiting caspase-activated 
DNase which causes DNA fragmentation (Ahn et al. 2005). 
1.2.2 NPM as a shuttling/transport chaperone 
In addition to its nuclear functions, NPM shuttles between the nucleolus and cytoplasm 
acting as a chaperone for both ribosomes and histones (Lindström 2011). Using leucines 
42 and 44, NPM binds to CRM1 in order to exit the nucleus (Yu et al. 2006), bringing 
with it rRNA as well as the small 40S and large 60s ribosomal units (Maggi et al. 2008). 
NPM also regulates mRNA, limiting the length of the poly(A) adenylation tail and 
facilitating mRNA export. Depletion of NPM leads to hyperadenylation and 
accumulation of mRNA in the nucleus without greatly affecting mRNA half-life 
(Sagawa et al. 2011). 
1.2.3 Cytoplasmic roles 
Although predominantly localised in the nucleolus, NPM has been found to interact 
with the microtubule kinesin Eg5. NPM’s DNA/RNA binding domain (residues 191-
294) interact with Eg5’s motor domain (residues 1-437), inhibiting the latter’s ATPase 
activity and promoting microtubule polymerisation (Wang et al. 2010).  
NPM also associates with the centrosome inhibiting its duplication until phosphorylated 
by cyclin E-cdk2 on residue T199 during mitosis (Tokuyama et al. 2001). CycE/cdk2 
licenses centrosomes for duplication by phosphorylating NPM on threonine 199 
(T199). This causes the dissociation of NPM away from the centrosome allowing it to 
duplicate. NPM remains phosphorylated throughout S/G2 phases, supposedly by being 
phosphorylated by cycA/cdk2 (Tokuyama et al. 2001) and only re-associates with the 
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centrosomes later in mitosis where it is phosphorylated by the mitotic cyclin B-cdk1 
complex (Peter et al. 1990) on T234 and T237 (Cha et al. 2004). Centrosome 
association in mitosis is dependent on phosphorylation by the centrosome maturation 
kinase Nek2A and NPM remains at centrosomes until after the sister chromatids have 
separated in anaphase (Yao et al. 2004).  
Because CycA and E both activate the same cdk (cdk2), they are functionally redundant 
and can compensate for each other’s loss albeit with a delay in S-phase progression 
(Hanashiro et al. 2008). Elevated cyclin E causes premature NPM phosphorylation 
resulting in centrosome overduplication (Mussman et al. 2000; Nakayama et al. 2000; 
Saavedra et al. 2003).  
NPM is also phosphorylated on serine 4 by polo-like kinase (plk) 2 in S phase and this 
phosphorylation is sustained through into M phase by Plk1. Mutating serine 4 to the 
phosphomimetic glutamate or aspartic acids results in centrosome overamplification 
and the opposing mutation to alanine causes elongated or multi-lobed nuclei (Zhang et 
al. 2004a; Krause and Hoffmann 2010). 
In addition to its 37/38 kDa full-length form, NPM is known to be cleaved to 30 kDa 
which is further cleaved to 20 kDa to modulate cytokine production by macrophages. 
This is achieved primarily by caspase 7 cleavage at Asp213 producing the p30 fragment 
which is further cleaved by cathespin B to produce the p20 fragment (Guery et al. 2011). 
In natural killer (NK) cells, NPM is cleaved by granzyme M at Leu158 which facilitates 




1.2.4 Lesser known post-translational modifications 
Although initially identified as a phosphoprotein (Jones et al. 1981), NPM is subject to 
a variety of post-translational modifications (PTMs) and as such, regularly appears in 
Western blots as multiple bands. NPM interacts with PARP-1 and PARP-2 and is poly-
(ADP-ribosyl)ated in response to ionising radiation (Ramsamooj et al. 1995; Meder et 
al. 2005).  
NPM is also sumoylated on lysine (K) 230 and 263. Mutation of the former site 
increases phosphatidylinositol-3,4,5-trisphosphate and suppresses DNA fragmentation 
while mutation of the latter abolishes binding to retinoblastoma protein, leads to 
reduced nucleolar and centrosomal localisation, and is more vulnerable to caspase-3 
cleavage and apoptosis (Tago et al. 2005; Liu et al. 2007). NPM also undergoes 
ubiquitination, both in the canonical pathway that leads to proteasomal degradation 
(Itahana et al. 2003) as well as a less conventional  lysine 6-linked poly-ubiquitin chain 
catalysed by BRCA1 E3 ligase (Sato et al. 2004). Although the exact downstream 
events of lysine 6-linked poly-ubiquitination are unknown, the fact that both NPM and 
BRCA1 are localised to centrosomes and regulated by Cdk2 suggests that a cell cycle 
role is likely (Hayami et al. 2005; Okuwaki 2008). 
1.3 NPM in cancer 
1.3.1 Oncogenic roles 
Wild-type NPM is overexpressed in a variety of carcinomas including gastric (Tanaka 
et al. 1992), colon (Nozawa et al. 1996), ovarian (Shields et al. 1997), breast (Skaar et 
al. 1998), liver (Yun et al. 2007), brain (Kuo et al. 2015) and prostate (Subong et al. 
1999). NPM overexpression in proliferating cells compared to resting or differentiating 
cells may also drive tumourigenesis by its role in ribosome biogenesis (Maggi et al. 
2008). Cancer cells exhibit enlarged nucleoli, the site of ribosome synthesis (Ruggero 
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and Pandolfi 2003) so the upregulation of NPM would increase the production of 
ribosomes which would, in turn, contribute to the elevated protein synthesis rate needed 
for the high rate of cellular replication in cancer cells (Grisendi et al. 2006). 
Overexpression of NPM can also stimulate increased RNA transcription by 
sequestering HEXIM1, an inhibitor of positive transcription elongation factor b (P-
TEFb), which in turn transcribes RNA polymerase II (Gurumurthy et al. 2008; Lew et 
al. 2013). 
Elevated wtNPM also inhibits apoptosis (Ye 2005), sequestering p53 in the nucleus and 
preventing it from localising to the mitochondria where it would otherwise activate 
proapoptotic proteins such as Bax an Noxa which would induce the release of 
cytochrome c, triggering apoptosis (Dhar and St Clair 2009). NPM itself interacts 
directly with Bax, preventing it from translocalising to mitochondria to facilitate 
mitochondrial outer membrane permeabilization (Lo et al. 2013). 
In addition to inhibiting cell death, NPM is also correlated with metastatic invasiveness 
by enhancing the MAP kinase/ERK pathway (Liu et al. 2012b; Loubeau et al. 2014). 
NPM also drives DNA synthesis by binding to and stimulating DNA polymerase α 
activity in cooperative synergy with retinoblastoma protein (Takemura et al. 1999). 
Overexpression of NPM bypasses G1/S and G2/M phase checkpoints, reduces 
commitment to myeloid differentiation and protects against enhance survivability to 
DNA damage and oxidative stress (Li et al. 2006; Du et al. 2010).  
NPM also enhances the activity of other oncogenes. For example, NPM interacts with 
the oncogenic transcription factor FOXM1 in cancer and immortal cells but not normal 
cells. Without the maintenance and stabilisation of FOXM1 by NPM in the nucleus, 
cell growth is inhibited both in vitro and in vivo (Bhat et al. 2011).  
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Lastly, NPM potentiates the Warburg effect by transcriptionally repressing the 
gluconeogenesis enzyme fructose-1, 6-bisphosphatase 1, promoting aerobic glycolysis 
instead of oxidative phosphorylation and thereby providing more resources for nucleic 
acid synthesis (Zhu et al. 2015). 
1.3.2 NPM as a tumour suppressor 
Paradoxically, NPM also exhibits properties of a haploinsufficient tumour-suppressor: 
hypomorphic, heteryzygous or knocked down nucleophosmin (NPM) levels cause 
genomic instability (Colombo et al. 2005), one of the ‘enabling characteristics’ of 
tumourigenesis (Hanahan and Weinberg 2011). NPM+/- mice develop myeloid and 
lymphoid malignancies and deletion of chromosome 5q arm, where the NPM gene is 
situated, is frequently found deleted in lung cancers (Mendes-da-Silva et al. 2000; 
Sportoletti et al. 2008). It seems therefore that NPM exhibits the “goldilocks” trait: 
cellular homeostasis requires an intermediate amount of NPM and too much or too little 
leads to oncogenesis.  
1.3.3 Haematological cancers 
NPM is also implicated in haematological malignancies, where consistent and recurrent 
clonal chromosomal aberrations are more common than in solid tumours (Kaye 2009). 
Approximately 80% of all cancers with clonal chromosomal abnormalities are blood 
cancers. The most famous, or perhaps, infamous of these is the Philadelphia 
chromosome of chronic myeloid leukaemia (Figure 1.3). In this classic textbook 
example, the translocation of the q arms of chromosomes 9 and 22 cause a gene fusion 
product with increased tyrosine kinase activity (Mitelman et al. 2007). This leads to 
activation of multiple signal transduction pathways that contribute to many of the 
hallmarks of cancer: reduced apoptosis, decreased dependence on growth factors, 
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impaired interaction with stroma and extracellular matrix and increased proliferation 
(Deininger et al. 2005).  
 
Figure 1.3 Chromosome aberrations in cancers 
Cytogenetic analysis can often reveal recurrent abnormalities that provide a ‘smoking gun’ 
that is sufficient for diagnosis (pathognomonic). Left panel, white arrows, translocation of 
chromosomes 9 and 22 found in the vast majority of chronic myeloid leukaemia (CML); 
right panel, example of the genetic anarchy of a solid tumour (bladder cancer). Adpated from 
Aplan, 2006.  
 
In about 50% of anaplastic large cell lymphoma, the N-terminus of NPM (which 
contains an oligomerisation domain) is fused with the C-terminus of anaplastic 
lymphoma kinase (which contains the kinase domain) due to a t(2;5)(p23;q35) 
chromosome translocation. This causes oligomerisation and activation of the kinase and 
downstream signalling leading to lymphomagenesis. Much rarer are t(5;17) and 
t(3;5)(q25;q35) chromosomal translocations which are found in acute promyelocytic 
leukaemia and acute myeloid leukaemia, respectively. The former results in an NPM-
retinoic acid receptor-α fusion that inhibits differentiation while the latter causes NPM-
myeloid leukaemia factor 1 fusion whose role in leukaemogenesis remains to be 




Figure 1.4 The N-terminal portion of NPM  
The oligomerisation domain (residues 1-110) is found with gene fusions in various blood 
tumours. Adapted from Lim & Wang, 2006. 
 
1.4 Acute Myeloid Leukaemia 
Acute myeloid leukaemia or AML is a heterogeneous haematological malignancy 
which is diagnosed as more than 20% immature/undifferentiated myeloblasts in the 
blood or bone marrow according to the World Health Organisation (Hasserjian 2013). 
Symptoms include haemorrhages, weakness, anaemia and susceptibility to infections 
(Moore 1964) and treatment involves leukaepheresis, bone marrow transplantation and 
chemotherapy (Grimwade et al. 2001). AMLs can be classed according to the 
morphology of the myeloblasts as is done in the French-American-British classification 
system (de Jonge et al. 2011). However, the WHO has proposed a revised system that 
is more dependent on karyotype and gene mutations which are more useful and relevant 
for prescribing treatment and establishing prognosis (Vardiman et al. 2009).  
1.5 NPMc 
Specific to around one-third of acute myeloid leukaemia (AML) cases is a cytoplasmic 
form of nucleophosmin with a frameshift mutation in the 12th and final exon (Falini et 




Figure 1.5 NPMc’s frame-shift mutation.  
Alignment of the four-base insertions (red letters), their effects on amino acid sequence and 
percentage out of 52 NPMc cases. Additional amino acids in green highlight, tryptophan 
resideus in yellow and substituted residues in grey. Reproduced with permission from Falini et 
al. 2005, Copyright Massachusetts Medical Society. 
 
Although the exact sequence and location of the 4-base insertion may vary between 
patients, the end result is the same (Figure 1.5): The abolition of tryptophans 290 and/or 
288 which causes a disruption of the hydrophobic core needed to maintain of the 
tertiary structure of the C terminus and NoLS (Grummitt et al. 2008) as well as the 
acquisition of a nuclear export signal (NES) at the C-terminus, in addition to one 
already present at residues 94-102 (Falini et al. 2006). As such, NPMc is 4 amino acids 
longer (298 residues) than wtNPM (294 residues). Evidence shows that this 
unstructured C-terminal domain has a strong tendency to form amyloid-like aggregates, 
although how this could translate to the (dys)function of NPMc in the cell remains to 
be elucidated  (Di Natale et al. 2015). 
The mutation is stable as can be seen in the NPMc-expressing cell line OCI-AML3 and 
in by comparing de-novo AML samples with relapsed cells from the same patient 
(Meloni et al. 2009). A small proportion of chronic myelomonocytic leukaemia also 
display the NPMc mutation and these patients are more likely to progress to AML and 
have lower survival rate (Peng et al. 2015).  
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Despite the heterozygous nature of the mutation, the oligomerisation domain at the 
protein's N-terminus, which remains functional, binds to wild-type NPM (wtNPM) and 
exports it out of the nucleus in a dominant negative manner. Overexpression of wtNPM 
increases the NoLS load on an oligomer and can rescue NPMc back to the nucleolus 
(Bolli et al. 2009). 
Approximately 85% of NPMc-positive AML cases are cytogenetically normal (Estey 
2010) and it is more common in female adult patients (Falini et al. 2007). It is associated 
with increased stem cell maintenance HOX gene expression (Alcalay et al. 2005) and 
is prognostically favourable in the absence of FLT3-Intenal Tandem Duplication 
(ITD) mutation. In general, the FLT3-ITD mutation is prognostically unfavourable but 
in older patients (>60 years of age), the presence or absence of NPMc has more 
influence on prognostic survival (Becker et al. 2010; Röllig et al. 2010). Furthermore, 
NPMc+ patients are twice as likely to have the FLT3-ITD mutation that those with 
wtNPM (Rau and Brown 2009). 
With multiple protein-interaction partners, the cytoplasmic delocalisation of NPM is 
bound to have pleiotropic effects and there are various ways NPMc contributes to 
leukaemogenesis. NPMc+AML displays unique and distinct miRNA and mRNA 
profiles (Garzon et al. 2008) and has a reduced ability to protect the tumour suppressor 
ARF from degradation (Figure 1.6), leading to a dampened p53 response (Colombo et 
al. 2006). ARF binds to the p53 ubiquitinator, Hdm2, and promotes its degradation 
thereby stabilising p53 (Zhang et al. 1998).  
 
Figure 1.6 NPMc supresses p53 and enhances cell survival 
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1.5.1 Location, location, location 
The old property agent’s mantra seems to be a common theme for NPMc’s oncogenic 
role: the C-terminal frame-shift mutation appears to affect the localisation of cellular 
NPM and little else; its binding ability and dynamics with other various protein partners 
remain largely unchanged and it is the mislocalisation of these protein partners that 
cause carcinogenesis. 
For example, HAUSP (herpes virus-associated ubiquitin specific protease) is a 
deubiquitinator of PTEN whose tumour suppressor function is dependent on its nuclear 
localisation which is facilitated by its monoubiquitination. Both wtNPM and NPMc can 
bind to HAUSP but in the former case, wtNPM is maintaining HAUSP in the nucleus 
where it sequesters HAUSP and prevents it from deubiquitinating PTEN. PTEN then 
remains active in its monoubiquitinated state in the nucleus. In NPMc+ cells, there is 
less NPM in the nucleus to inhibit HAUSP so PTEN becomes deubiquitinated and 
leaves the nucleus into the cytoplasm where it is polyubiquitinated. Any HAUSP 
brought into the cytoplasm by NPMc is also sequestered and inactivated leading to 
accumulation of polyubiquitinated PTEN and its eventual degradation (Noguera et al. 
2013).  
Similarly, both wtNPM and NPMc can bind to the ubiquitin ligase Fbw7γ. In the 
nucleus, Fbw7γ ubiquitinates the myc oncogene for degradation but in NPMc+ cells, 
Fbw7γ is exported into the cytoplasm where it is degraded, increasing myc’s stability 
as well as the transcription of myc target genes (Di Fiore 2008; Bonetti et al. 2008).  
Miz1, a transcription factor for cell cycle inhibitors p15 and p21, requires wtNPM as a 
co-activator. NPMc retains its binding ability to Miz1 but exports it to the cytoplasm 
where is it degraded thereby reducing cell cycle arrest and promoting cell growth 
(Wanzel et al. 2008).  
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In cell death, NPM can inhibit caspases 6 and 8 but wtNPM’s nucleolar localisation 
prevents this from having a significant effect on the cell. NPMc, however, is localised 
to the cytoplasm where the caspases are. NPM’s interaction domains with the caspases 
are towards the N-terminus of the protein and do not seem to be affected by NPMc’s 
mutation at the C-terminus. It is this retention of caspase inhibition ability that inhibits 
the extrinsic cell death response and promotes cell survival (Leong et al. 2010). NPMc’s 
inhibition of caspases 6 and 8 also suppresses myeloid differentiation. In both mouse 
and zebrafish models, overexpression of NPMc leads to accumulation of hematopoietic 
progenitor cells (Bolli et al. 2010; Cheng et al. 2010) and downregulation of NPM leads 
to increased caspase 6 and 8 activity, differentiation and apoptosis (Yi et al. 2015).  
This concept of opposing effects in the nucleus versus cytoplasm is not new.  p53 is 
also known to have a ‘Janus’ personality depending on its subcellular location; 
inhibiting autophagy and apoptosis by caspase 9 in the cytoplasm (Tasdemir et al. 2008; 
Callen 2013; Chee et al. 2013) but promoting transcriptional activation of autophagy 
and apoptotic genes in the nucleus (Brady and Attardi 2010). 
1.6 Mitosis 
Mitosis is known as the process by which cells divide their duplicated genetic material 
between two daughter cells. But in addition to DNA, other subcellular organelles are 
subject to this division as well, either stochastically during cytokinesis or in 
coordination with cytoskeletal structures. The former strategy is applicable to high-
copy number organelles such as mitochondria while low-copy or single-copy organelles 
like the centrosome or Golgi apparatus tend to opt for the latter strategy. Daughter cells’ 
organelles therefore are not usually made de novo but are multiplied from pre-existing 
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templates inherited from the mother cell (Nunnari and Walter 1996). Let’s look at how 
some of this is achieved. 
1.6.1 Endoplasmic reticulum and Golgi apparatus 
While the endoplasmic reticulum (ER) was initially thought to fragment and be 
distributed stochastically (Warren and Wickner 1996), recent studies have shown that 
(Lu et al. 2009), at least in some cells, ER is partitioned by association with cortical 
actin at the plasma membrane and also with microtubules while still maintaining its 
cisternal structure (Figure 1.7).  
 
Figure 1.7 Distribution of endoplasmic reticulum during mitosis. 
ER, endoplasmic reticulum; RER, rough ER. Adapted from McCullough & Lucocq 2005. 
 
There is less consensus on the distribution of the Golgi. While some observe the 
fragmentation of the Golgi and subsequent stochastic partitioning (Cabrera-Poch et al. 
1998), others observe the absorption of the Golgi into the ER which reconstitutes the 
former upon completion of mitosis (Zaal et al. 1999). This discrepancy may result from 
the use of different Golgi makers as some Golgi proteins may coalesce with the ER 
while others remain associated with Golgi fragments (Rabouille and Jokitalo 2003).  
 18 
 
1.6.2 Endosomes and lysosomes 
Endosomes are the mechanism by which cells uptake larger macromolecules from their 
environment and usually lead to metabolic degradation in fusion with lysosomes. The 
migration of endosomes appears to be dependent on their maturity. Early endosomes 
are positioned around centrosomes, away from the metaphase plate, during metaphase. 
As anaphase proceeds, they migrate over to the minus ends of shortening microtubules 
and adopt a juxtaposed position to the centrosome as the nuclear membrane 
reassembles. On the other hand, late endosomes and lysosomes are less ordered and are 
more passively distributed (Dunster et al. 2002). 
1.6.3 Mitochondria 
Despite being a high-copy number organelle, there is evidence to show that 
mitochondria are actively localised to the cleavage furrow during mitosis (Lawrence 
and Mandato 2013a). Inhibition of microtubules with nocodazole or taxol abolished the 
accumulation of mitochondria at the cell’s equator and the authors suggest that this 
localisation may be needed to meet the energy requirement for cytokinesis (Lawrence 
and Mandato 2013b). 
1.6.4 Nucleoli 
With the dissolution of the nucleus during mitosis, the structure of the nucleoli is also 
disassembled. The nucleolus is organised around ribosome biogenesis with fibrillar 
centres in which the ribosomal DNA are housed, the dense fibrillary component where 
rRNAs are processed and further processing and ribosome assembly in the outer most 
granular component (Hernandez-Verdun et al. 2010). RNA transcription begins to 
decrease at the start of prophase and cease by anaphase along with the dissociation of 
nucleolar proteins including NPM (Gébrane-Younès et al. 1997; Leung et al. 2004). 
Furthermore, the phosphorylation of NPM by cdk1 on at least four threonine residues 
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in its ribonuclease domain (T199, T219, T234, and T237) prevent its rRNA binding 
ability and nucleolar localisation (Okuwaki et al. 2002; Negi and Olson 2006). 
Nucleolar components then surround condensed chromatin, forming a perichromosoal 
layer around chromosomes. How this layer is maintained is poorly understood but 
hitchhiking onto the precisely coordinated separation of DNA ensures that nucleolar 
components are likewise equally distributed (Hernandez-Verdun 2011).  
As can be seen, microtubules not only govern the partitioning of DNA during mitosis 
but also that of other subcellular organelles. However, one hardly hears of diseases 
which are caused by inaccurate distribution of other organelles. DNA, however, is the 
source of genetic information from which other cellular machinery is constructed so 
defects in DNA replication or distribution become the source of mutations that persist 
in diseases such as cancer. 
1.7 Centrosomes 
Cancer has been described as a microevolutionary process, not least because it defies 
the cooperation and collaboration that is characteristic of multicellular organisms 
(Alberts et al. 2002). It has been suggested that, in order to overcome the defences setup 
to stop such selfish behaviour, genome instability develops early in cancer development 
as a means to get rid of tumour suppressors and activate oncogenes (Boland and 
Ricciardiello 1999). One source of genome instability is centrosome dysfunction. The 
small size (1-2μM, Fukasawa 2005) of this organelle betrays the complexity of its 
duplication and its importance in the faithful segregation of chromosomes in mitosis. 
1.7.1 Structure and organisation 
The centrosome consists of two fibre-linked centrioles surrounded by a number of 
proteins collective called pericentriolar material (Figure 1.8). One centriole containing 
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appendages which are needed for microtubule nucleation is known as the mother 
centriole and the other, the daughter centriole. It is only just before mitosis that the 
daughter centriole acquires the appendages for spindle pole formation (Bornens 2002). 
 
Figure 1.8 Structure of a centrosome 
Diagram of centrioles surrounded by PCM. Adapted from Fukasawa 2005. 
 
1.7.2 Duplication 
Like DNA replication, centrosome duplication is semi-conservative, triggered by cdk2 
and has strict controls to ensure that it only occurs once per cell cycle (Blow and Dutta 
2005; Tsou and Stearns 2006b; Tsou and Stearns 2006a).  
1.7.2.1 Disengagement and licensing 
Duplication actually begins at the end of the previous M phase with centriole 
disengagement in which the orientation between the mother and daughter centrioles is 
loosened. Although the mechanisms of various factors have yet to be resolved, it is 
generally agreed upon that separase-mediated cleavage of cohesin is necessary but not 
sufficient (Nakamura et al. 2009; Schöckel et al. 2011) for disengagement. This makes 
sense as cohesin also holds sister chromatids together and their separation occurs much 
earlier in M phase. Pericentrin B (PCNTB)/kendrin has been proposed to be one of the 
additional factors needed to be cleaved by separase at R2231. The resulting short C-
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terminal fragment is released and degraded while there is a delay in the dissociation of 
the N-terminal fragment, supposedly via oligomerisation with as yet uncleaved PCNTB 
(Matsuo et al. 2012; Lee and Rhee 2012).  
However, the knockdown of separase leads to only a delay in centriole disengagement 
as polo-like kinase 1 (Plk1) eventually overcomes this. The total failure of centriole 
disengagement requires knockdown of both separase and plk1 (Tsou et al. 2009). In 
addition, Plk1 further participates in the next step of centrosome duplication (licensing) 
by phosphorylating NPM on serine 4. It is centrosome licensing that NPM was first 
implicated in (Section 1.2.3) and it is centrosome licensing that ensures duplication is 
only initiated once per cell cycle (Nigg 2007).  
Nevertheless, it would be ignorant to presume that NPM is the sole licenser. Mps1 is 
also phosphorylated by cdk2, stabilising it at centrosomes and promoting duplication. 
Mps1 is so named because yeast cells lacking it entered mitosis with monopolar 
spindles (Winey 1991; Pike and Fisk 2011). Mutation of the cdk2 phosphorylation site 
T468 to alanine results in proteasome-dependant removal of Mps1 from centrosomes 
(Kasbek et al. 2007). This explains why overexpression of Mps1 in itself is insufficient 
to trigger centrosome reduplication because Mps1 can still be moved from the 
centrosome into the cytoplasm (Pihan 2013).  
Plk4 also licenses centrosomes. Like plk1, plk4 activity peaks during mitosis. During 
interphase, plk4 levels are kept low during interphase via autophosphorylation which 
triggers ubiquitination and subsequent proteasome degradation (Holland et al. 2010; 
Guderian et al. 2010). Mutation of phosphorylation sites leads to plk4 accumulation and 




1.7.2.2 Nucleation and elongation 
After licensing, plk4 then initiates procentriole nucleation. Overexpression of plk4 
induces multiple procentrioles instead of only just one which does not affect the mitosis 
immediately after but carries the centrosome amplification phenotype into the next cell 
cycle. Spindle assembly abnormal 6 (Sas-6) acts upstream of plk4 as Sas-6 knockdown 
abolishes procentriole assembly even in the presence of plk4. Plk4 subsequently 
recruits other factors such as γ-tubulin and CPAP (putative homolog of C. elegans Sas-
4) (Kleylein-Sohn et al. 2007). Sas-6 is crucial to forming what is known as the 
cartwheel assembly by self-assembling into a nine-spoked wheel (van Breugel et al. 
2011), each spoke consisting of an Sas-6 homodimer 40˚ apart (Figure 1.9). In mitosis, 
anaphase-promoting complex in association with the adaptor protein Cdh1 
ubiquitinates Sas-6’s C-terminus, lowering cellular levels of Sas-6 to prevent 
extraneous procentriole nucleation (Strnad et al. 2007).  
 
Figure 1.9 SAS-6 forms the basis of centriole's nine-fold symmetry. 
Sas-6’s N-terminus forms the central ring of the cartwheel assembly whose lumen is 23nm 
wide. The central coiled-coil domain forms spokes that radiate outwards to the C-terminus 
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where other centriole factors bind and is also the location of ubiquitination leading to 
degradation. Adapted from Kitagawa et al. 2011. 
 
Now that the new centriole has been nucleated, addition factors such as γ-tubulin and 
its interaction partner NEDD1 (neural precursor cell expressed, developmentally down-
regulated 1) are recruited to elongate it during S to G2 phase (Haren et al. 2006). CPAP 
(centrosomal P4.1-associated protein) also participates in elongation (Tang et al. 2009). 
Overexpression of CPAP leads to long centrioles which recruit extra pericentriolar 
materials which form extra procentrioles (Kohlmaier et al. 2009). Elongation is capped 
by centriolar coiled-coil protein of 110 kDa also known as centrosomal protein of 110 
kDa (CP110). Depletion of CP110 leads to elongated centrioles (Chen et al. 2002) so 
during late S to G2/M phase, CP110 is stabilised by interaction with the 
deubiquitinating enzyme USP33 which prevents CP110 degradation (Li et al. 2013). 
1.7.2.3 Maturation 
With the completion of centriole growth, the next step is to accumulate pericentriolar 
material (PCM) and dissolve the link between the two centrosomes so that they may 
migrate to opposing ends of the cells to separate chromatids. PCM accumulation is 
largely controlled by plk1 which phosphorylates NEDD1 at serine 418 to activate its γ-
tubulin recruiting capability. Recruitment of other PCM factors such as Cep192 
(centrosomal protein of 192 kDa), pericentrin and Cep215 are also dependant on plk1 
activity (Haren et al. 2009).  
Unlike centriole disengagement, dissolution of the intra-centrosomal link is not 
facilitated by cleavage of the fibres but by evicting linker components. This is 
controlled by Nek2 (NIMA-related kinase 2) phosphorylation of fibre components. 
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Nek2 overexpression leads to premature centrosome separation (Fry et al. 1998) and 
siRNA knockdown prevents it, causing mitotic delay (Fletcher et al. 2005).  
Most importantly, plk1 recruits the motor protein Eg5 to centrosomes to facilitate 
bipolar movement of the duplicated centrosomes. Without functional Eg5, mitosis is 
halted in prometaphase due to monopolar spindles (Whitehead and Rattner 1998; 
Kapoor et al. 2000).  
The above is a greatly simplified reduction of the centrosome duplication process, 
without which it would not be possible for the cell to divide. Owing to its inhibitory 
role in centrosome duplication, one would think that the accumulation of NPM in the 
cytoplasm would prevent cellular division. Yet NPMc+ AML is able to overcome this 
and become leukaemogenic. Clearly, the advantages of cytoplasmic delocalisation 
outweigh any compensatory mechanism needed to permit centrosome duplication and 
this thesis proposes that phosphorylation of NPM is that very compensatory mechanism 
that allows the cell cycle to proceed. So it is perhaps ironic that the path that lead to this 
discovery started with the investigation of what can be considered the antithesis to cell 
division: cell death.  
1.8 Cell death 
In addition to increasing the rate of cell proliferation, the cancer progenitor must also 
evolve ways to avoid following commands to die, whether they originate intracellularly 
or externally from other cells. Apoptosis is arguably the most well-defined method of 
cell death and is contingent on cysteine aspartyl-specific proteases or caspases (Testa 
and Riccioni 2007). As their name implies, caspases are cleaved at specific aspartate 
residues turning the inactive zymogen into an activated form. Caspases are classed into 
initiator (caspases 8, 2, 9 and 10) and effector (caspases 3, 6 and 7) caspases. The former 
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are unique to whether the death signal originated from transmembrane receptors or 
internally by compromising mitochondrial integrity. Both sources of initiator caspases 
converge on effector caspases.  
1.8.1 Extrinsic apoptosis 
Extrinsic apoptosis is triggered via activation of transmembrane receptors by external 
ligands such as FasL, tumor necrosis factor (TNF) and TNF-related apoptosis-inducing 
ligand (TRAIL) and these can be harnessed in anti-cancer therapy. Of these three listed 
above, TRAIL is the most likely candidate as it does not induce undesirable side effects 
(Ogasawara et al. 1993; Bazzoni and Beutler 1996). Unfortunately, most cases of AML 
are TRAIL-resistant (Wuchter et al. 2001; Testa and Riccioni 2007) mediated by 
TRAIL receptor downmodulation or mutation of the downstream caspase 8 (Suh et al. 
2003). Co-treatment with drugs that enhancing TRAIL response have shown some 
promise but are yet untested in the clinic (Hasegawa et al. 2006; Szegezdi et al. 2006).  
Downstream of extrinsic transmembrane receptor is the adaptor molecule Fas 
associated protein with death domain (FADD) which possess another barrier to cell 
death. Levels of FADD are positively correlated with prognosis and (Tourneur et al. 
2004) so even if the upstream receptor is expressed/functioning, the signal may not be 
transmitted further is there is not enough FADD to respond (Lewis et al. 2000). 
Alternatively, FADD may be counteracted by FADD-like inhibitory proteins (FLIP) 
which bind to FADD and competitively inhibit binding to pro-caspase 8 which would 
otherwise activate it (Tschopp et al. 1998). Caspase 8 may itself be altered to caspase 
8L which lacks the protease domain but still maintains binding ability to FADD, acting 
in a similar fashion to FLIP (Himeji 2002; Mohr et al. 2005).  
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Interestingly, caspase 8 is also involved in another form of cell death called necroptosis. 
The name derives from the fact that it is morphologically like necrosis but is controlled 
by signalling like apoptosis. In this pathway, inactive caspase 8 forms a complex with 
FADD, recruiting receptor-interacting proteins (RIP) 1 and 3 which potentiate 
downstream signalling, causing fission of mitochondria and increased reactive oxygen 
species. Conversely, active caspase 8 cleaves RIP1/3, favouring the apoptotic response 
in the absence of caspase inhibition (Vandenabeele et al. 2010). Active caspase 8 also 
mutes necroptosis by cleaving cylindromatosis (CYLD) which would normally 
deubiquitinated RIP1 so that it is available to form the necroptosome (O’Donnell et al. 
2011). Because NPMc inhibits caspase 8, one would expect necroptosis to be 
potentiated. However, recent work in the lab that this alternative death pathway is also 
inhibited by NPMc. RIP1 cleavage is elevated in NPMc expressing cells although 
further work is needed to elucidate the mechanism (Bte Ahmad 2014). 
1.8.2 Intrinsic (mitochondrial) apoptosis 
The energy factory of the cell is, perhaps, ironically also the trove of pro-apoptotic 
effectors such as cytochrome c, Smac/DIABLO, Omi/HtrA2 and AIF which are 
released upon irreparable cellular damage or unfavourable environmental growth 
conditions (Ishizaki et al. 1995; Fulda and Debatin 2006). This occurs by proteins which 
open pores in the mitochondrial membrane from the Bcl2 family.  
In AML, upregulation of anti-apoptotic Bcl-2 members such as Bcl-2 (Campos et al. 
1993; Klampfer et al. 1996; Traver et al. 1998) and Bcl-XL (Konopleva et al. 2002; 
Minami et al. 2003; Bagrintseva et al. 2005)  as well as inactivation of pro-apoptotic 
proteins such as Bad and Bax (Martelli et al. 2006) is a common strategy to avoid cell 
death.  Moreover, a high Bcl-2 to Bax ratio is associated with expression of the stem 
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cell marker CD34 (van Stijn et al. 2003). Bcl-2 may be upregulated by the transcription 
factor CCAAT/enhancer binding protein α (C/EBPα) which is mutated in 10% of AML.    
These mutants, lack either the N-terminal transactivation domain or the C-terminal 
DNA-binding domain, cooperate with nuclear factor-κB (NF-κB) p50 to transactivate  
Bcl-2 (Paz-Priel et al. 2005).  Therefore, it is no surprise that Bcl-2 is a potential 
druggable target in the clinic (de Lima et al. 2004; Dai et al. 2005; Marcucci et al. 2005).   
Bcl-2 prevent mitochondria membrane permeabilisation and a major consequence of 
this is the release of cytochrome c which goes on to form the apoptosome complex with 
apoptotic protease activating factor 1 (Apaf1) and caspase 9. Leukaemic cells have been 
shown to have low Apaf1 levels due to DNA methylation and treatment with the 
methylation inhibitor 5-aza-2’-deoxycytidine increased Apaf1 levels (Furukawa et al. 
2005).  
The downstream caspase of the apoptosome, caspase 3, is correlated with poor 
prognosis (Estrov et al. 1998) and found to be elevated in relapsed AML but not de 
novo cases indicating that it is a secondary event and not involved in the primary 
leukaemogenesis (Gronda et al. 2005).  
The major caspase inhibitor of the intrinsic pathway is X-linked inhibitor of apoptosis 
protein (XIAP) which is found to be correlated with poor survival (Tamm et al. 2004b; 
Tamm et al. 2004a) more so than survivin, another caspase inhibitor (Adida et al. 2000). 
Small molecule inhibitors of XIAP are able to decrease XIAP levels and sensitise AML 
cells to TRAIL-induced apoptosis (Carter et al. 2005; Carter et al. 2006; Carter et al. 
2008).  
The first chapter of results (chapter 3), therefore, entertains the possibility that NPMc 




In the course of investigating XIAP regulation, it was noted that the centrosome-related 
phosphorylation site threonine 199 was more phosphorylated on NPMc than wtNPM. 
This warrants further investigation as T199 phosphorylation is a pre-requisite to 
centrosome duplication and unphosphorylated NPM inhibits centrosome duplication. 
Correct timing and amount of phosphorylation is critical for maintaining normal 
karyotype and incorrect centrosome duplication can lead to genomic instabilities such 
as aneuploidies commonly found in cancer. Coincidentally, 85% of NPMc cases have 
a normal karyotype. Therefore we hypothesized that the hyperphosphorylation of 
NPMc was somehow related to the fact that a greater proportion of subcellular NPM 
was now localized in the cytoplasm and hence has greater accessibility to the 
centrosome.  
Hence, the remaining majority of this thesis aims to look into how this elevated 





2 Methods and Materials 
2.1 Cell Culture  
HEK293T cell lines (a kind gift from Dr Low Boon Chuan, NUS) were cultured in 
RPMI 1640 (Sigma, USA) supplemented with 10% fetal bovine serum (FBS, 
Invitrogen, USA) and 1% penicillin/streptomycin (PS, from PAA Laboratories GmbH, 
Austria). OCI-AML2 and 3 cell lines were cultured in alpha-Modified Eagle's Medium 
(αMEM, Sigma, USA) supplemented with 20% FBS and 1% PS.  
Cells were maintained in a 37°C incubator with a humidified atmosphere of 5% CO2 
and passaged at 90% confluence.  
2.2 Drug treatment  
Cells were treated for 16 hours with 10μM of GW8510 (Sigma, USA) in dimethyl 
sulfoxide (DMSO), 4 hours with 10nM of leptomycin B in 70% methanol solution as 
provided by Sigma, USA. Cycloheximide was dissolved in DMSO and used at 
100μg/ml and 10μg/ml for HEK239T and OCI-AML2/3 cells, respectively.  
2.3 S100 cell lysis 
For GST pulldown, HEK293T cells that had been transfected (Section 2.7) with were 
pelleted at 2000 revolutions per minute (rpm)and washed once with 1x PBS and 
resuspended in 100μl of S100 buffer [20mM Hepes-KOH, pH 7.5, 10mM KCl, 1.5mM 
MgCl2, 1mM EDTA, 1mM EGTA, 3mM dithiothreitol, 1% protease inhibitor cocktail 
(Roche Molecular Biochemicals, USA)]. The cell suspensions were then sonicated on 
ice in 1sec pulse, 1sec rest cycles for a total of 30 cycles. Samples were then centrifuged 
at 20,000g for 20min. The supernatant was collected and protein concentration was 




2.4 GST pulldown 
NPM proteins that had previously been cloned into pGEX4T-3 were transformed into 
Escherichia coli (E. coli) BL21 and cultured overnight in 8ml of Luria-Bertani (LB) 
broth with 100μg/ml ampicillin (Sigma, USA). The culture was upscaled to 80ml and 
0.1M isopropyl β-D-1-thiogalactopyranoside (IPTG) was added 6 hours later to activate 
expression of GST proteins. After overnight expression, bacteria was pelleted and 
resuspended in 10ml of binding buffer [1% Triton-X in PBS, 1% protease inhibitor 
cocktail (Roche Molecular Biochemicals, USA)]. Cells were lysed by sonication on ice 
at 40% amplitude for a total of 4mins in 9secs pulses with 9secs of rest in between 
pulses and then centrifuged at maximum speed (8500rpm) for 15mins. The supernatant 
was incubated with 25ul of glutathione sepharose 4B beads (GE, USA), that had been 
pre-washed once with PBS and once with binding buffer, for 1hour at room temperature 
with end-over-end rotation. Beads were then centrifuged at 500g for 5mins and washed 
twice with binding buffer and once in S100 buffer before overnight incubation at 4°C 
with 5mg of HEK293T S100 lysate as described above. The GST beads were pelleted 
the next morning and the excess supernatant lysate was removed. Beads were washed 
5 times with binding buffer before being boiled in SDS-PAGE loading buffer (62.5mM 
Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 1% β-mercaptoethanol, 2% w/v 
bromophenol blue) at 95˚C. A total of 100μg of S100 lysate was loaded as input. 
2.5 Total Cell lysis  
Cells from 6-well plates were centrifuged at 2000rpm for 5 min and washed once with 
PBS. The pelleted cells were resuspended in 100μl of hot SDS lysis buffer [100mM 
Tris-HCl pH8.0, 2% sodium dodecyl sulphate (SDS), 50mM dithiothreitol (DTT), 20% 
glycerol] and incubated at 85°C for 10mins. Samples were then sonicated at 40% 
amplitude for 15 s in 1 s pulses with 1 s of pause after each pulse followed by another 
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10 min incubation at 85°C. Protein concentration was estimated by measuring 
absorbance at 280nm using the Thermo Scientific NanoDrop 2000™ 
Spectrophotometer. 
2.6 Electrophoresis and Western Blot  
Proteins were separated under denaturing conditions in 12% polyacrylamide gels and 
electroblotted onto nitrocellulose membranes using Trans-Blot SD semi-dry transfer 
(Bio-Rad, USA) at 15V for 35 min. Membranes were blocked with 3% w/v skimmed 
milk in Tris buffered saline (TBS) with 0.1% v/v Tween-20 (TBST) for 15mins 
followed by overnight incubation with primary antibodies diluted in 5% w/v bovine 
serum albumin (BSA) in TBS. Mouse anti-cNPM (Developmental Biology Lab, NUS) 
and mouse anti-NPM (Invitrogen, USA) were used at a 1:2000 dilution. Mouse anti-
actin (Sigma, USA) was used at a 1:10,000 dilution. Rabbit anti-NPMpT199, cyclin B 
and XIAP (Cell Signalling Technology, USA) were used at a 1:1000 dilution. Rabbit 
anti-cyclin A, cdk4 and cdk2 (Santa cruz, USA), anti-Flag (Cell Signalling Technology, 
USA) and anti-NPMpS125 (Abcam, UK) were used at a 1:2000 dilution. Mouse anti-
PP1β and anti-c-myc (Santa Cruz, USA) were used at a 1:2000 dilution. Rabbit anti-
NPMpS4 (Cell Signalling Technology, USA) was used at a 1:5000 dilution. Rabbit 
anti-NPMp234/7 (Abcam, UK) was used at a 1:1000 dilution. The following day, blots 
were washed three times (5 min each) in TBST and incubated with horse-radish 
peroxidase (HRP) conjugated goat anti-mouse or anti-rabbit secondary antibodies 
(Santa Cruz Biotechnology, USA). Protein bands were visualized with Pierce 
Biotechnology SuperSignal West Pico or Femto chemiluminescent substrate following 
the manufacturer’s recommendations. 
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2.7 Transfection  
Cells were seeded into wells of 6-well plates containing autoclaved microscope cover 
slips such that they were 70-80% confluent at the time of transfection. 5μg of DNA was 
transfected into each well using 10μl of Lipofectamine 2000 (Invitrogen, USA) per well 
in serum-free RPMI. The next day, cells were checked for fluorescence. 
For cdk2 knockdown, 100nM of control or cdk2 siRNA (Santa Cruz) was transfected 
with 10µl of Dharmafect (GE healthcare) for 48 hours.  
2.8 Immunofluorescence 
HEK293T cells were grown directly on glass coverslips while AML2/3 cells were 
cytospun onto microscope slides at 600 rpm for 5 mins. 
For NPMpT199 and PP1β staining, cells were fixed with 4% paraformaldehyde in 
phosphate-buffered saline (PBS) for 30 mins, followed by a wash with PBS and 5 mins 
permeabilization in digitonin (50μg/ml in PBS) and quenched for 5 mins with 50mM 
NH4Cl in PBS. For γ-tubulin or cdk2 staining, cells were fixed/permeabilised in 50:50 
ice-cold acetone:methanol for 30 mins and then washed once with PBS before 
proceeding to blocking. Blocking buffer consists of 5% goat serum and 2% horse serum 
in PBS for 1 hr at room temperature. Samples were incubated with γ-tubulin primary 
antibody (T3559, Sigma) at 1:300 dilution factor, cdk2 primary antibody (sc-748, Santa 
Cruz) at 1:50 dilution factor, PP1β primary antibody  (A1088, Abclonal)  or phospho-
NPMT199 primary antibody (3541, Cell signaling) at 1:500 dilution factor in blocking 
buffer at room temperature for 1 hr. Alexa Fluor-conjugated anti-mouse or anti-rabbit 
immunoglobulins (Life Technologies) were used as secondary antibodies (1:1000 in 
blocking buffer for 1 hour at room temperature) and cell nuclei were visualized with 
DAPI. Fluorescent images were taken using BX60 microscope (Olympus) and 
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processed using Image J. 100 cells were counted per experiment for centrosome 
counting. 
2.9 Cell cycle analysis 
Cells were fixed in 1ml of ice-cold 70% ethanol for at least 3 hours then washed once 
with PBS and resuspended in Millipore Muse cell cycle reagent (MCH100106, Merck 
Millipore) as per the manufacturer’s instructions. 10,000 events per sample was 
measured in the Muse Cell Analyzer (0500-3115, Merck Millipore). Experiments were 
conducted in triplicate and two-sample unequal variance T-test was used to calculate p-
value. 
2.10 Site-directed mutagenesis 
The primers used for site-directed mutagenesis are listed in Table 1. 
 




















pAcGFP-NPMc plasmid was used as a template along with 1x pfu reaction buffer, 
200μM dNTP mix, 0.8μM each of forward and reverse primers and 2μl of pfu turbo 
polymerase (Stratagene, USA) in a total volume of 50μl. Initial denaturation was run at 
95˚C for 5min followed by 25 cycles of 95˚C for 30secs, 48˚C for 45secs and 72˚C for 




2.11 Colourimetric caspase activity assay 
Cells were treated with 250nM of staurosporine for 24 hours and lysed in S100 buffer 
as described above. 50μg of cell lysate was incubated in the reaction buffer with 200μM 
of LEHD-pNA substrate (for caspase 9) or DEVD- pNA substrate (for caspase 3) 
according to the manufacturer’s instructions (BioVision, USA). Absorbance at 405nm 
was read at 2 minute intervals for 16 hours.  
2.12 Phosphorylated H2A.X assay 
Phosphorylated H2A.X was measured using Muse® Cell Analyser (0500-3115, Merck 
Millipore) after staining with Muse® H2A.X Activation Dual Detection Kit 
(MCH200101, Merck Millipore) which contains anti-phospho-Histone H2A.X 
(Ser139)-Alexa Fluor®555 and anti-Histone H2A.X-PECy5 conjugated antibodies. 
2.13 Cell death assay 
Live and apoptotic cells were analysed via annexin V and PI staining using Muse® 
Annexin V and Dead Cell Kit (MCH100105, Merck Millipore) according to the 
manufacturer‘s protocol. Samples were processed using Muse® Cell Analyser (0500-
3115, Merck Millipore). 
2.14 Statistics 
All statistics were computed in Microsoft Excel. All error bars in figures represent 
standard error. P-value was calculated based on student’s T-test with unequal variance. 
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3 XIAP regulation and expression in NPMc expressing 
cells 
3.1 Introduction 
The cytoplasmic localisation of NPM has previously been shown to inhibit caspases 6 
and 8 of the extrinsic cell death pathway leading to mitigated TRAIL-triggered 
apoptosis and inhibited myeloid differentiation (Leong et al. 2010). But what of the 
intrinsic (mitochondrial) cell death pathway involving caspases 9, 3 and 7?  
XIAP is a known inhibitor of caspases 9, 3 and 7 (LaCasse 2013). Clinical data also 
show that patients with high levels of XIAP confer poor response to chemotherapy 
(Ibrahim et al. 2012) leading to poorer prognosis (Sung et al. 2009). It is no surprise, 
therefore, that XIAP is being targeted by therapeutic drugs and there are studies 
evaluating their effectiveness in both AML (Schimmer et al. 2011) as well as solid 
cancers (Mahadevan et al. 2013).  
3.1.1 Rationale 
Previous work in the lab has shown that NPMc overexpression causes increased X-
linked inhibitor of apoptosis (XIAP) protein levels and that this occurs by the 
transcription factor Sp1 but not other pathways such as RIP, JNK or NF-κB (Loo 2009; 
Wong 2010). XIAP is the most potent inhibitor of caspase and also the most widely 
expressed IAP (Obexer and Ausserlechner 2014). It has also been found that the NPMc-
expressing cell line OCI-AML3 expresses XIAP at higher levels compared to other 
leukaemic cell lines, HL-60, KG-1 and K562 (Carter et al. 2003). In addition, XIAP 
expression levels are more strongly correlated with prognosis than other members of 
the IAP family such as Survivin (Tamm et al. 2000).  
Further work in the lab found that HEK293T cells overexpressing GFP-tagged NPMc 
(GFP-NPMc) show an upregulation of XIAP compared to GFP or GFP-tagged wild 
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type NPM (GFP-wtNPM). In addition, chromatin immunoprecipitation showed that 
binding of the transcription factor Sp1 to the XIAP promoter was higher in GFP-NPMc 
overexpressing cells than GFP-wtNPM and GFP overexpressing cells. However, Sp1 
expression levels did not correlate with promoter binding. Therefore, it is more likely 
that post-translational modification/s and/or protein-protein interactions are responsible 
for regulating Sp1 promoter binding specificity and activity.   
As a transcription factor, Sp1 is well documented to be regulated by post-translational 
modifications (Li et al., 2004; Tan & Khachigian, 2009). For example, phosphorylation 
by cdk2 complexed with and activated by cyclin A increased DNA binding and 
transcription of a reporter gene; furthermore, overexpression of cyclin A increased 
mRNA expression of the reporter gene (Fojas de Borja et al., 2001). Cdk2 is already 
known to be linked to XIAP expression; its inhibition with the drug GW8510 decreased 
both XIAP mRNA and protein levels without affecting other anti-apoptotic proteins 
such as Bax, Bak or Bcl2. This downregulation of XIAP was accompanied by increased 
apoptosis in non-small cell lung cancer cells (Dong et al. 2006). Since Sp1 is a known 
transcription factor of XIAP (Lee et al. 2006) and can be regulated by cdk2 
phosphorylation, it is reasonable to postulate that the downregulation of XIAP reported 
by Dong et al may be caused by decreased phosphorylation by cdk2 and hence promoter 
binding of Sp1.  
As previously mentioned, expression of Sp1 responsive genes is correlated to cyclin A 
levels (Fojas de Borja et al. 2001) and cdk2, like all cdks, requires cooperation with a 
cyclin in order to function. Is cyclin A upregulated in NPMc cells? And if so, how so? 
As a multi-functional protein, NPM can bind to many proteins and its delocalisation 
can therefore cause the export of these proteins into the cytoplasm. One such protein is 
fbw7γ, a ubiquitin ligase and hence, degradation trigger for oncogenes such as cyclin 
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E, myc, jun and notch (Welcker and Clurman 2008). It’s delocalisation into the 
cytoplasm by NPMc induces its degradation thereby stabilising myc and increasing 
expression of myc’s target genes (Bonetti et al. 2008). Therefore, we postulate that this 
stabilisation of myc in NPMc-expressing cells leads to increased expression of cyclin 
A and hence increased Sp1 binding and XIAP expression. This chapter, therefore, aims 
to study the mechanism by which XIAP may be regulated in NPMc-expressing cells.  
 
Figure 3.1 Hypothesis of XIAP regulation in NPMc-expressing cells.  
3.2  Results 
To facilitate this study, two cell line systems were used: haematopoietic myeloid 
progenitor cell lines OCI-AML2 and OCI-AML3; and human embryonic kidney with 
T-antigen (HEK293T) stable cell lines overexpressing GFP, GFP-wtNPM and GFP-
NPMc. The former system is more reflective of the disease but the disadvantages are 
that OCI-AML2 and OCI-AML3 (henceforth referred to as AML2 and AML3, 
respectively) are not isogenic as they are isolated from different patients and are also 
more difficult to maintain in cell culture, having the propensity to differentiate if not 
properly passaged. For this reason, the HEK293T stable cell lines, previously 
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established in the lab (Chan 2010) via lentiviral transfection, are used to complement 
AML2/3. 
3.2.1 NPM binds to Fbw7γ which regulates myc stability 
To corroborate the findings of Bonetti et al. (Bonetti et al. 2008), a GST pulldown was 
used on lysates of HEK293T cells transfected with flag-tagged Fbw7γ. Consistent with 
their report, GST-NPM was able to pull down flag-fbw7γ as the latter was depleted in 
the supernatant (Figure 3.2, right most lane), indicating that flag-fbw7γ had been 
removed from the cell lysate by NPMc. Deletion fragments of NPM show that the N-
terminal fragments are unable to pull down flag-fbw7γ more than the GST control while 
the C-terminal 187-294 residues were able to pull down flag-fbw7γ to a similar degree 
compared to the larger 118-294 amino acid fragment. This indicates that the last 108 
amino acids are sufficient to bind flag-fbw7γ and does not require structural support 
from other domains.  
 
Figure 3.2 NPM’s C-terminal binds to fbw7γ. 
GST pull-down of Fbw7γ with NPM fragments as labelled. Blot probed with anti-flag. 
 
It is unclear whether the C-terminal 112 amino acids of NPMc can bind to fbw7γ in a 
similar way to the C-terminal 108 residues of wtNPM. NPMc’s last 50 residues have 
been shown to be more unfolded than wtNPM (Grummitt et al. 2008; Scaloni et al. 
2010) so fbw7γ binding may require full-length NPMc unlike wtNPM which can still 
bind fbw7γ with only the last 108 amino acids. A GST-NPMc truncation mutant would 
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be needed to determine whether NPMc’s C-terminal frame-shift mutation, which only 
changes the last 7 residues, could affect its ability to bind fbw7γ.  
Consistent with the hypothesis and previous findings (Bonetti et al. 2008), the stability 
of myc protein is dependent on NPMc localisation. Treatment of cells with leptomycin 
B, an inhibitor of nuclear export resulted in a decrease of myc protein levels in NPMc 
expressing HEK293T cells as well as AML3 but not GFP, GFP-wtNPM controls or 
AML2. Reverse transcription polymerase chain reaction (RT-PCR) of myc mRNA 
showed that the decrease in myc protein levels was not due to decreased myc gene 
transcription as cDNA levels did not show a corresponding decrease but in fact 
increased (Figure 3.3).  
 
Figure 3.3 Decrease of myc upon leptomycin B (LepB) treatment is not due to decrease in 
mRNA levels.  
Cells were treated with 5nM of leptomycin B for 4 hours then run on Western blot or had their 
RNA extracted and then RT-PCRed for the indicated gene. IB, immunoblot.  
 
The stability of myc was also assayed using cycloheximide, an inhibitor of protein 
translation. In NPMc-overexpressing HEK293T cells, myc was more stable than in GFP 
or GFP-wtNPM overexpressing counterparts. However, in the myeoblastic AML2 and 
3, myc was less stable in the NPMc expressing AML3 than in AML2, being degraded 
to a ~43kDa fragment (Figure 3.4). This 43kDa fragment was still detectable by the 
myc antibody (9E10) raised against residues 408-439 so any cleavage would likely 
occur at the N-terminus leaving the DNA binding domain at the C-terminus unaffected. 
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Therefore the transactivating ability of the 43kDa fragment should not be negated. This 
fragment was not seen in the HEK293T cells.  
 
Figure 3.4 Cycloheximide (CHX) chase assay showing that myc is more persistent in 
NPMc-expressing 293T than GFP or wtNPM counterparts.  
Contrary to hypothesis, myc in AML3 is not more stable than AML2. However, note the 
~43kDa band which still retains the C-terminal (detected by 9E10 antibody) DNA binding 
domain. 
3.2.2 XIAP protein level is inconsistent with mRNA expression and 
does not decrease upon cdk2 inhibition 
Next, the protein levels of cyclin A were compared. Contrary to the hypothesis, there 
is no significant difference between the GFP, GFP-wtNPM and GFP-NPMc 
overexpressing HEK293T nor AML2 and AML3. However, RT-PCR of XIAP was still 
consistent with the hypothesis of the NPMc expressing cells having higher expression 




Figure 3.5 XIAP mRNA levels are higher in NPMc-expressing cells but Cyclin A levels do 
not differ significantly.  
Actin was used as a loading control for protein and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) for RT-PCR. 
 
As reported by Dong et al (Dong et al. 2006), treatment with cdk2 inhibitor GW8510 
decreased XIAP levels in non-small cell lung cancer cells. To verify that GW8510 does 
indeed inhibit cdk2, cells were treated with 5 and 10μM GW8510 in DMSO and the 
effect on cell cycle compared to controls. As expected, the drug decreased the number 
of cells in G0/G1 phase with a corresponding increase in the number of cells in S and 
G2/M phase as cdk2 inhibition would prevent the proper completion of S/G2 and 
attenuate the progression through M phase (Figure 3.6). Interestingly, in both AML and 
HEK293T, the cells expressing NPMc had more cells in G0/G1 than those with 
wtNPM. There was little significant difference between the 5 and 10μM treatments so 




Figure 3.6 GW8510 treatment inhibits mitotic progression causing cells to build up in S 
and G2/M phase.   
Cells were treated with stated amounts of drug overnight or the solvent DMSO as control then 
fixed and stained with potassium iodide before analyses by low cytometry. Upper panel, 
HEK293T stably expressing GFP, GFP-wtNPM or GFP-NPMc; Lower panel, hematopoietic 
cell lines OCI-AML2 (AML2) and OCI-AML3 (AML3). Results are representative of three 
independent experiments. Error bars represent standard error.  
 
Although cdk2 inhibition produced the expected effect on cell cycle, it did not replicate 
the results reported by Dong et al. There was also no observable decrease in XIAP 
levels upon GW8510 treatment in all cells except for the GFP overexpressing 
HEK293T (Figure 3.7). XIAP levels also seemed unperturbed in both AML2 and 3 
upon treatment. However, XIAP levels also were lower in NPMc expressing cells, 
contrary to the mRNA results. Although AML3 displayed higher XIAP protein levels 
than AML2, NPMc-overexpressing 293T did not display this same phenotype. 




Figure 3.7 XIAP levels are not increased in NPMc expressing cells and do not decrease 
upon GW8510 treatment.  
Cells were treated for 16 hours with 5μM of cyclin-dependant kinase 2 (cdk2) inhibitor 
GW8510 which abolished the phosphorylation of  both endogenous as well as GFP tagged 
exogenous NPM at threonine 199 (T199). NPMc(C)-, GFP (G) and wtNPM (W) overexpressing 
cells.  
 
As further verification that cdk2 was indeed being inhibited by GW8510, blots were 
also probed for phosphorylated NPM (threonine 199, T199) known to be 
phosphorylated by cdk2 as a permissive precursor to centrosome duplication 
(Tokuyama et al., 2001). GW8510 was able to decrease phosphorylation in the 
HEK293T cells but not AML2 and AML3. Interestingly, the NPMc expressing cells 
showed a higher level of T199 phosphorylation compared to AML2 and GFP or GFP-
wtNPM overexpressing HEK293T.  
 
3.2.3 NPMc-expressing cells have greater caspase 3 and 9 activity 
To further corroborate the low XIAP levels in the HEK293T stables, the activity of 
caspases 3 and 9 which XIAP inhibits were measured using a colourimetric assay which 
uses colourless substrates that turn yellow when cleaved by specific caspases. The 
amount of yellow substrate can then be quantified by the absorbance of 405nm light 
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and is positively correlated with caspase activity. Cells were treated with the initiator 
of apoptosis staurosporine known to activate caspases by compromising mitochondrial 
integrity resulting in the release of cytochrome c, caspase 3 and caspase 9 (Chae et al. 
2000; Belmokhtar et al. 2001; Fiorucci et al. 2002; Zhang et al. 2004b). Cells expressing 
NPMc had higher caspase 3 and 9 activity for both staurosporine and control treatments 
with the solvent DMSO indicating that NPMc did not provide any protection against 
the intrinsic cell death induced by staurosporine but instead increased caspase 3 and 9 
activity (Figure 3.8). The lower XIAP level of the NPMc-expressing cells is therefore 






Figure 3.8 NPMc-expressing cells have higher caspase 3 and 9 activity than GFP or 
wtNPM counterparts. 
HEK293T cell lines stably expressing GFP, GFP-wtNPM (wtNPM) or GFP-NPMc (NPMc)  
were treated with 250nM of staurosporine (STS) for 24 hours and lysed in S100. 50μg of cell 
lysate was incubated in the reaction buffer with 200μM of LEHD-pNA substrate (for caspase 
9, upper panel) or DEVD- pNA substrate (for caspase 3, lower panel) according to the 
manufacturer’s instructions (BioVision, USA). Absorbance at 405nm was read at 2 minute 






















































3.3.1 The complexities of XIAP regulation. 
Although increased XIAP expression was observed in the NPMc-expressing AML3 
cells compared to wtNPM-expressing AML2, NPMc-expressing HEK293T cells had 
decreased XIAP levels compared to GFP or wtNPM counterparts. Therefore it is 
unlikely that NPMc is directly involved in XIAP regulation. Indeed, another study have 
also found XIAP mRNA to be inconsistent with protein levels (Tamm et al. 2000). 
We were unable to replicate the results by Dong et al with regards to the downregulation 
of XIAP in response to the cdk2 inhibitor GW8510 perhaps because they were cell 
specific; although there has been precedence for the downregulation of XIAP in 
response to another small molecule cdk inhibitor, flavopiridol, in breast cancer cells 
(Wittmann et al. 2003).  
Even though XIAP may be successfully transcribed and translated, it does not guarantee 
protection against intrinsic cell death. XIAP can be inhibited by Smac/DIABLO which 
blocks its binding ability to caspases (Obexer and Ausserlechner 2014). Similar to 
NPM’s role in caspase 6 and 8 inhibition, XIAP must also be in the cytoplasm to inhibit 
caspases; relocalisation into the nucleus by interaction with XIAP –associated factor 1 
leads to decreased caspase 3 activity and cell death (Liston et al. 2001; Russell et al. 
2008). XIAP may also be cleaved by the very caspases it is meant to inhibit: XIAP’s 
inhibition of intrinsic cell death can be overcome by the activation of caspase 3 through 
the extrinsic pathway, cleaving and inactivating XIAP (Deveraux et al. 1999). Finally, 
XIAP’s degradation can be accelerated by ubiquitin ligases in addition to its own 
autoubiquitination ability (Hiramatsu et al. 2014). Phosphorylation by Akt on serine 87 
inhibits this, stabilising XIAP and increasing resistance to cell death (Dan et al. 2004). 
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XIAP in AML3 is already known to be regulated by PI3 kinase and to a lesser extent 
MEK kinase (Carter et al. 2003) and while the status of these pathways in AML2 is not 
known, it is an interesting possibility to explore in future. Therefore the higher 
expression of XIAP in AML3 cells compared to AML2 should not be taken as solid 
evidence for the resistance to cell death or promotion of cell survivability as NPMc+ 
AML have favourable prognoses in clinical settings. 
3.3.2 The non-isogenicity of AML2/3. 
Another limitation is that AML2 and AML3 are not isogenic despite both being classed 
under the same group according to the French-American-British classification system 
(Table 2). The former was isolated from the peripheral blood of a 65-year-old male 
while the latter was likewise isolated from a 57-year-old male. Both cell lines have 
hyperdiploid karyotype but AML2 has much more cytogenetic abnormalities than 
AML3 (Wang et al. 1989). On a molecular level, although both AML2 and AML3 have 
wild-type p53, the former overexpresses Mdm4 which binds to p53, sequestering and 
stabilising it in the cytoplasm. AML3 therefore has less stable p53 than AML2 which 
may affect apoptotic response (Tan et al. 2014). AML3 also has a reduced ability to 
repair DNA lesions compared to AML2 as NPMc binds to the repair polymerase, DNA 
polη, exporting it, resulting in its degradation (Ziv et al. 2014). Contradictorily, AML3 
is more sensitive than AML2 to chemotherapeutics targeting DNA damage such as 
doxorubicin and etoposide (Lew et al. 2011). DNA methylation states may also be 
different between AML2 and AML3. Both cell lines have mutations in the 
methyltransferase domain of DNA methyltransferase 3A but AML2’s is towards the N-
terminus (R635) while AML3’s is at the C-terminus (R882C). These may affect the 
enzyme’s activity differently and hence give the two cell lines different epigenetic 
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profiles (Tiacci et al. 2012). NPMc+ AML is already known to have a distinct DNA 
methylation signature (Figueroa et al. 2010). Therefore the upregulation of XIAP in 
AML3 may be due to differences in gene regulation unrelated to NPM status.  
AML2 and 3 also displayed different c-Myc degradation profiles; the former retaining 
full-length myc for a longer period after translation inhibition while myc in AML3 was 
quickly cleaved by an unknown protease to 43kDa (Figure 3.4). Shortened variants of 
myc have been known to be biologically active. Myc-nick is cleaved at lysine 298 by 
calpains, recruits the acetyltransferase GCN5 to tubulins, increases α-tubulin 
acetylation and promotes myoblast differentiation (Conacci-Sorrell et al. 2010). MycS 
is produced from an alternative start codon and is missing ~100 amino acids of the N-
terminus. Although this deletes one of the four Myc boxes in the transactivation 
domain, MycS still retains most of the function of Myc and can rescue phenotypes of 
myc null cells such as enhanced cell proliferation and anchorage-independent growth 
(Xiao et al. 1998). Therefore the biological activity of the 43kDa fragment should not 




Table 2 Peculiarities of AML2 versus AML3. 
Der, derived from; del, deletion; inv, inversion; t, translocation; dup, duplication; ins, insertion; 
CD, cluster of differentiation marker; HLA-DR, human leukocyte antigen-D related; ANLL, 
Acute nonlymphocytic leukaemia; RB, retinoblastoma; FAB, French-American-British 
category . 
 OCI-AML2 OCI-AML3 
Morphology single, round to oval cells in 
suspension 
single and clumps, mostly round 
cells growing in suspension 
Doubling 
time 
about 30-50 hours about 35-40 hours 
Immunology CD3-, CD4+, CD13+, CD14-, 
CD15+, CD19-, CD33+,  
CD34-, CD68+, HLA-DR+ 
CD3-, CD4+, CD13+ CD14-, 
CD15+, CD19-, CD34+, CD68+, 
HLA-DR- 
Cytogenetics human hyperdiploid karyotype 














sideline with +der(5) - carries 
apparent variant translocations 
involving several ANLL 
breakpoints: 1p36, 3q21, 3q26 
(megakaryocytic abnormalities), 
12p13, 17q24 (FAB-M4) 
human hyperdiploid karyotype - 
48(45-50)<2n>X/XY, +1, +5, +8, 
der(1)t(1;18)(p11;q11), ins(5p), 
del(13)(q13q21), 
dup(17)(q21q25) - sideline with 
r(Y)x1-2 - hemizygous for RB1 
3.3.3 A new direction: The elevation of T199 phosphorylation. 
Perhaps the most interesting find in this chapter is the elevation of the centrosome-
related phosphorylation site threonine 199 (T199) in NPMc because it occurred in both 
the AML system and the HEK293T stable cell lines, implying that it is unlikely to be 
caused by differences in genetic backgrounds.  
Phosphorylation was decreased upon treatment with cdk2 inhibitor GW8510 in 
HEK293T but not AML cells. This could be due to a lack of cell permeability in AML 
or other cdks compensating for the downregulation of cdk2 activity caused by GW8510. 
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It is known that there exists a certain level of redundancy among both cyclins and cdks 
(Satyanarayana and Kaldis 2009). Cdk2-/- mouse are viable albeit meiosis is affected 
leading to sterility (Ortega et al. 2003). So it is possible that other cdks (e.g. cdk4 and/or 
cdk1) could compensatorily phosphorylate T199 although why this occurs in AML but 
not HEK293T is unknown. It could be that AML2 and 3, originating from cancer cells, 
have a greater propensity for non-canonical cyclin/cdk activity that would support cell 
proliferation if any particular cyclin/cdk were to be somehow incapacitated during the 
tumour transformation process. Whereas HEK293T is derived from an otherwise 
healthy aborted foetus (van der Eb 2001) and would have less impetus to stray from 
orthodox cyclin/cdk activity. 
Nevertheless, there is a lack of literature on the topic of NPMc and centrosomes. While 
the role of wtNPM in centrosome licensing has been known for some time (Okuda et 
al. 2000), it seems that the pathological displacement of NPM into the same subcellular 
compartment as the centrosome (cytoplasm, as opposed to being physically separated 
by the nuclear envelope) has received little attention even though it would stand to 
reason that such a delocalisation could be part of leukaemogenesis especially in light 
of the correlation between NPMc and normal karyotype (85%, Estey 2010) which is in 
part maintained by faithful centrosome duplication. The rest of this thesis therefore 
begins to fill this gap. 
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4 Causes of increased NPMc phosphorylation 
4.1 Introduction 
During the cell cycle, NPM is phosphorylated by cyclin dependant kinase 2 on 
threonine 199 (T199) which causes the dissociation of NPM away from the centrosome 
and permits duplication to occur. Mutation of the phosphorylation site to non-
phosphorylatable alanine prevents phosphorylation and hence centrosome duplication, 
thus increasing the number of cells with one centrosome and decreasing the number of 
cells with two centrosomes (Tokuyama et al., 2001). However, a more recent study, in 
which endogenous NPM was knocked out in Arf−/−/p53−/−/Mdm2−/− triple knockout 
mouse embryonic fibroblasts, showed that infection with a non-phosphorylatable NPM 
mutant at the corresponding mouse phosphorylation site (T198) was able to rescue 
centrosome numbers to a similar degree as those in infected with wild-type NPM 
(Brady et al. 2009). The authors postulated that NPM’s suggested role as a centrosome 
duplication inhibitor may be a downstream effect of its ribosome biogenesis/protein 
production role since the non-phosphorylatable T198A NPM mutant was able to rescue 
ribosome levels to NPM knockouts. However an alternate possibility is that other 
centrosomal factors were able to license duplication or the non-phosphorylatable NPM 
could be sequestered away from the centrosome by other cytoplasmic factors hence 
allowing duplication. NPM, being a multi-functional protein, has multiple binding 
partners so there is no shortage of candidates in this regard. 
In NPMc+ AML, the cytoplasmic load of NPM increases and the results in this chapter 
aim to eliminate other possible causes of elevated NPMcT199 phosphorylation, further 




4.2.1 Increased phosphorylation is not dependent on kinase levels, 
activation or localization 
As mentioned in the previous chapter, we suspected that there might be compensatory 
phosphorylation by other kinases (whether cyclin-dependant or not) occurring in the 
AML system.  To explore this possibility, the HEK293T stable cell model was chosen 
for its isogenicity, ease of culture and transfectability which enable simplify 
experiments. To verify that cdk2 was the main kinase in the HEK293T system, cells 
were transfected with 100nM of cdk2 siRNA for 48 hours and phosphorylation levels 
of NPM detected on Western blot.  
Knockdown of cdk2 greatly reduced phosphorylation confirming previous literature 
that cdk2 is the predominant kinase for T199 phosphorylation (Adon et al. 2010). 
NPMc’s elevated phosphorylation is not facilitated by increased cdk2 expression as 
cdk2 levels did not differ between GFP, wtNPM or NPMc overexpressing cells (Figure 
4.1a). 
To confirm the elevated phosphorylation of NPMc was not due to indirect effects of 
transgene insertion, HEK293T cells were transfected with GFP, GFP-wtNPM or GFP-
NPMc and treated with cdk2 inhibitor GW8510 (Johnson et al. 2005; Dong et al. 2006; 
Diaz-Corrales et al. 2008). GFP-NPMc is more phosphorylated than GFP-wtNPM 
despite similar total NPM (Figure 4.1b). This phosphorylation was greatly diminished 
upon cdk2 inhibition across all cell types. Neither cyclin E nor cdk2 were elevated in 
GFP-NPMc overexpressing cells, indicating that the increased phosphorylation of 
NPMc does not require increased activation or protein levels of cdk2. In fact, cyclin E 
was expressed at slightly lower levels in GFP-NPMc overexpressing cells despite the 
elevated phosphorylation of NPMc. Upon GW8510 treatment, cyclin E levels increased 
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as would be expected because cdk2 is unable to stimulate the progression to mitosis and 
more cells become arrested and build up in S phase when cyclin E is expressed (Keck 
et al. 2007).  
 
Figure 4.1 NPMc hyperphosphorylation is not dependent on cdk2 levels or activation 
(a) Western blot shows that knockdown of cdk2 reduces T199 phosphorylation and that NPMc 
phosphorylation is elevated compared to wtNPM. . HEK293T cell lines stably expressing GFP 
(G), GFP-wtNPM (W) or GFP-NPMc (C) were transfected with 100nM of cdk2 siRNA for 
48hours. (b) Western blot of HEK293T cells transfect with GFP (G), GFP-wtNPM (W) or GFP-
NPMc (C) for 24 hours before drug treatment selected cell cycle proteins in response to 5μM 
GW8510 treatment for 24 hours shows cdk2 inhibition abolished the phosphorylation of both 
endogenous as well as GFP tagged exogenous NPM at threonine 199 (T199). Adapted from 
Chan and Lim 2015. 
 
Furthermore, immunofluorescence staining of cdk2 shows that it is not restricted to any 
subcellular location, neither does its localization differ between wild-type or NPMc-
overexpressing cells (Figure 4.2a). However, since the staining with the antibody from 
Santa Cruz appeared non-specific, immunofluorescence was repeated with another 
cdk2 antibody from a different source (Abcam, Figure 4.2b). The Abcam antibody 
showed a more nuclear staining pattern consistent with the manufacturer’s datasheet. 
Regardless, neither antibody displayed any preference for cdk2 in the cytoplasm so the 
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elevated phosphorylation of NPMc is therefore more likely due to the increased 
cytoplasmic load of NPM rather than the levels, activation or localization of cdk2.  
 
 
Figure 4.2 Cdk2 is not preferentially localised to the cytoplasm. 
Immunofluorescence staining of (a) Anti-cdk2 (H-298) from Santa Cruz (sc-748) and (b) Anti-
cdk2 from Abcam (ab6538). Bar=20μM. Adapted from Chan and Lim 2015. 
 
As there is a certain level of redundancy among cyclins and cdks (Satyanarayana and 
Kaldis 2009), the elevated phosphorylation of NPMc may be facilitated by the increased 
expression or activation or these other kinases. However, a brief panel of other cyclins 
and cdks (Figure 4.3) show that this is not the case. Levels of Cyclin B and cdk4 are 
not significantly different from GFP- and wtNPM-expressing controls and cyclin A and 
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cdk1 are slightly decreased in comparison. In addition, levels of the phosphatase which 
dephosphorylates T199, protein phosphatase 1 β (Lin et al. 2010), are similar in all three 
cell types. This further supports the hypothesis that NPM localisation is the main factor 
in determining T199 phosphorylation and not other extraneous protein interactions. 
 
Figure 4.3 Other cell cycle proteins and phosphatase are not elevated in NPMc-expressing 
cells. 
Western blot of HEK293T stable cell lines. G, HEK293T stably overexpressing GFP; W, 
HEK293T stably overexpressing GFP-wtNPM; C, HEK293T stably overexpressing GFP-
NPMc. PP1β, protein phosphatase 1 β; CycA, cyclin A; CycB, cyclin B; Cdk, cyclin dependant 
kinase. 
4.2.2 NPM phosphorylation is dependant on subcellular 
localisation 
As shown in the previous chapter, NPMc is more phosphorylated than wtNPM and this 
phosphorylation is abolished upon cdk2 inhibition with the drug GW8510. To further 
verify this and see whether this phosphorylation is dependent on NPM’s localisation, 
cells were pre-treated with leptomycin B for 1 hour before addition of DMSO or 
GW8510 and then blotted for phosphorylated NPM. After 1 hour, cells were briefly 
checked under a light microscope (Figure 4.4) for the relocalisation of NPMc to the 
nucleus. Inhibition of nuclear export did decrease phosphorylation of GFP-NPMc but 
not GFP-wtNPM. Leptomycin B also further enhanced the decrease in phosphorylation 





Figure 4.4 Leptomycin B causes relocalisation on NPMc into the nucleus but does not 
affect wtNPM or GFP localization. 
HEK293T stably expressing GFP, GFP-wtNPM (wtNPM) or GFP-NPMc (NPMc) were treated 
with 5nM leptomycin B (lepB, bottom 6 panels) for 24 hours. The localisation of NPMc (bottom 
right most panel) changes from cytoplasmic to nuclear as is consistent with the nuclear export 
inhibitor action of the drug. GFP and GFP-wtNPM do not show any visible change in 




Figure 4.5 Relocalisation of NPMc decreases T199 phosphorylation. 
Cells were treated with leptomycin B as per figure 2 and western blotted. Treatment with 
leptomycin B alone reduced T199 phosphorylation of NPMc but not wtNPM whereas cdk2 
inhibitor, GW8510 (5μM, 24 hrs) affected both wtNPM and NPMc. Co-treatment of leptomycin 
B with GW8510 further reduced the phosphorylation of NPMcT199. Lep B, leptomycin B; 
GW8510, cdk2 inhibitor. GFP, HEK293T stably overexpressing GFP; wtNPM, HEK293T 
stably overexpressing GFP-wtNPM; NPMc, HEK293T stably overexpressing GFP-NPMc. 
Adapted from Chan and Lim 2015. 
 
To investigate how the dephosphorylation of NPM might be facilitated, the localisation 
of protein phosphatase 1 β (PP1β) was visualised using immunofluorescence (Figure 
4.6). The nuclear localisation of PP1β suggests that the reduction in NPMc 
phosphorylation upon lepB treatment could be due to the accessibility of the 
phosphatase and NPM substrate upon relocalization of NPMc back into the nucleus. In 
untreated cells, the cytoplasmic pool of NPMc has a greater capacity to retain T199 




Figure 4.6 PP1β is localised to the nucleus. 
Immunofluorescence staining of PP1β in HEK293T overexpressing GFP, wtNPM or NPMc. 
Cells were fixed in paraformaldehyde and stained with rabbit anti-PP1β followed by anti-rabbit 
Alexa fluor 568 conjugate. Bar=10μM. 
4.2.3 More NPMc is phosphorylated earlier in the cell cycle than 
wtNPM 
As the movement of NPMc back into the nucleus was in itself sufficient to reduce 
phosphorylation, we hypothesise that the increased phosphorylation of NPMc is caused 
by the shear amount of NPM in the cytoplasm that needs to be phosphorylated during 
centrosome licensing. Immunofluorescence staining of NPMphosphoT199 shows that 
there is widespread phosphorylation of NPMc in the cytoplasm of NPMc 
overexpressing cells prior to nuclear breakdown causing a doughnut shaped staining 
pattern, whereas phosphorylation is only visible after nuclear breakdown in wtNPM 
and GFP overexpressing cells (Figure 4.7). This is consistent with the hypothesis since 
prior to nuclear breakdown in wtNPM-expressing cells, there would only be a small 
amount of NPM in the cytoplasm inhibiting centrosome duplication so only a small 
amount of phosphorylation is needed which is not visible. However in the NPMc-
expressing cells, much more NPM in the cytoplasm means that at the same stage in the 
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cell cycle when centrosome duplication is being initiated, more phosphorylation needs 
to occur. After nuclear breakdown, the NPM in the nucleus is no longer spatially 
restricted from preventing centrosome duplication so all the NPM is phosphorylated 
such that the phosphorylation is visible in both wtNPM and NPMc expressing cells.  
 
Figure 4.7 NPMc is phosphorylated earlier in the cell cycle than wtNPM.  
HEK293T stably expressing GFP, GFP-wtNPM (wtNPM) or GFP-NPMc (NPMc) were stained 
with rabbit anti-phosphoNPM(T199) followed by anti-rabbit Alexa fluor 568 conjugate. Unlike 
wtNPM and GFP expressing cells, immunofluorescence staining shows that cells expressing 
NPMc have phosphorylation before nuclear membrane dissolution resulting in a “doughnut” 




While there is a wealth of information on wtNPM’s centrosome function (Tokuyama et 
al. 2001; Tarapore et al. 2002; Okuda 2002; Cha et al. 2004; Wang et al. 2005; Shinmura 
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et al. 2005; Ma et al. 2006; Brady et al. 2009; Krause and Hoffmann 2010; Adon et al. 
2010; Ferretti et al. 2010; Yao et al. 2010; Wang et al. 2011; Reboutier et al. 2012; Xia 
et al. 2013) and NPMc’s role in AML (Alcalay et al. 2005; den Besten et al. 2005; 
Gurumurthy et al. 2008; Cilloni et al. 2008), there remains a gap in the literature of 
NPMc’s effects on the centrosome especially in the light of its correlation with normal 
karyotype (Di Fiore 2008).  
4.3.1 Possible causes of disparate phosphorylation 
This chapter has eliminated kinase expression levels and localization as a possible cause 
of increased NPMc phosphorylation (Figure 4.1 and Figure 4.2). Activation of the 
kinase is also unlikely to be responsible. NPMc-overexpressing cells had a lower level 
of cyclin E than GFP or GFP-wtNPM (Figure 4.1). This is counterintuitive because one 
might expect cyclin E which is an activator of cdk2 to be increased in order to stimulate 
cdk2’s kinase activity, thereby increasing NPMcT199 phosphorylation. The unvarying 
levels of other cyclins, cdks and phosphatase also fail to explain the increased 
phosphorylation of NPMc but it is the nuclear localisation of the phosphatase PP1β 
(Figure 4.6) that can explain the phosphorylation difference between nuclear wtNPM 
and cytoplasmic NPMc. This hypothesis would be supported if expression of a mutant 
PP1β with a nuclear export signal increased T199 phosphorylation of nuclear NPM. It 
would also be interesting to see whether other cdk2 targets are affected by the increased 
workload of NPMc phosphorylation. Since cdk2 is not upregulated in quantity or 
activity, the phosphorylation of other targets may be less efficient as they have more 
NPM to compete with.  
NPMc’s elevated phosphorylation could also be because of other activators of cdk2. 
RAB-like 6 isoform A (RABL6A) is known to interact directly with NPM and prevents 
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cdk2-mediated T199 phosphorylation. Knockdown of RABL6A induces centrosome 
amplification and increased NPMpT199 phosphorylation (Zhang et al. 2013). It would 
be interesting to see if and how this interaction is affected in NPMc. 
Another aspect yet to be explored is that NPMc may have a different binding capability 
to cdk2 than wtNPM. Immunoprecipitation would be able to show whether the C-
terminal mutation structurally affects NPM’s upstream portion to the point of affecting 
binding affinity to cdk2. It could be that the structural change of NPMc facilitates its 
increased phosphorylation by having a greater propensity for phosphorylation.  
While phosphorylation of both wtNPM and NPMc decreased in response to cdk2 
knockdown or chemical inhibition, only NPMc responded significantly to leptomycin 
B treatment, emphasising that localisation is the most likely cause of NPMc 
hyperphosphorylation. However, several questions remain about whether T199 
phosphorylation could confer increased protein stability as NPMc does not seem to be 
degraded in the cytoplasm unlike other proteins such as ARF and Fbw7γ. This issue 
should be addressed in future studies. 
4.3.2 CRM inhibitors and NPM 
Leptomycin B (lepB) works by inhibiting the nuclear export protein CRM1 
(chromosome region maintenance; also known as XPO1, Exportin-1). Originally found 
to be produced by Streptomyces sp. (Hamamoto et al. 1983), lepB occupies ~70% of 
the groove in CRM1 where the nuclear export signal (NES) of the cargo protein would 
normally sit (Sun et al. 2013). Once proposed as an anti-tumour agent, lepB’s cytotoxity 
lead to its discontinuation in clinical trials (Newlands et al. 1996) but it still remains a 
valuable research tool today due the relevancy of nuclear export inhibitors  (NEI) in 
cancer treatment. A number of NEIs have shown to be promising in clinical trials for 
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both haematological and solid tumours and AML is no exception (Ranganathan et al. 
2012; Gravina et al. 2014). Unlike the HEK293T overexpression system (Figure 4.4), 
treatment of AML3 with CRM1 inhibitor, KPT-185, results in nucleolar, not just 
nuclear, relocalisation. This is most probably because there is enough wtNPM in AML3 
to form hetero-oligomers with NPMc and pull the NPMc from the nucleoplasm to the 
nucleolus. In the HEK293T overexpression system, the amount of NPMc greatly 
outweighs wtNPM so even when NPMc re-enters the nucleus upon CRM1 inhibition, 
there is not enough wtNPM to overcome the lack of NoLS in the exogenous NPMc. 
This is supported by previous experiments showing that wtNPM and NPMc exist in a 
‘dose-dependent tug of war’ where localisation changes in concordance with titration 
of the two opposing NPM species (Bolli et al. 2009). Therefore, future experiments 
should focus on how the wtNPM:NPMc ratio affects NPM phosphorylation. 
Another CRM1 inhibitor, a recently identified fungal derivative, avrainvillamide 
(Wulff et al. 2007), has been shown to not only bind and inhibit CRM1 but also NPM 
itself, restoring nucleoplasmic as well as nucleoli localisation. Initially isolated from a 
tropical marine fungus (Fenical et al. 2000), avrainvillamide forms a reversible S-
alkylation bond with cysteine 275 (C275) of NPM. It binds 4.6 times faster to NPMc 
than wtNPM, probably due to the more unfolded state of the mutant making C275 more 
accessible. The additional cysteine 288 introduced by NPMc’s (mutant A, Figure 1.5) 
contributes minimally to drug binding (Mukherjee et al. 2014). The fact that 
avrainvillamide can bind to NPM’s C-terminus and induce nucleolic localisation 
implies that at least some of the tertiary structure of the nucleoli localisation signal is 
restored even though both tryptophans that form its hydrophobic core have been 
deleted. A 3D crystal or NMR structure of the drug and NPM would be invaluable in 
shedding light on how the disordered C-terminus is affected by avrainvillamide. 
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The cellular impact of such drugs is complicated by the dual role of CRM1 as a nuclear 
exporter as well as a centrosome localiser of which both functions are dependent on the 
same nuclear export signal (NES) of the cargo protein. Therefore CRM1 inhibitors like 
lepB would have a twofold impact on NPMc: 1) nuclear localisation and 2) inability for 
centrosome localisation. Avrainvillamide claims to do much more. Because this 
electrophilic antiproliferative drug binds to both NPM and CRM1, it not only 
perpetuates the two effects of CRM1 inhibition stated above but also restores C-
terminal structure leading to nucleolar localisation and inhibits protein phosphatase 1β 
which increases T199 phosphorylation, further exasperating the lack of NPM at 
centrosomes. 
4.3.3 Phosphorylation and centrosomes 
In addition to the restoration of wild-type nucleoli localisation, Mukherjee et al. 
(Mukherjee et al. 2014) document the dissociation of NPM away from centrosomes 
leading to overduplication. This response is similar to a previous report on lepB in 
which the authors suggest that, in addition to nuclear export, CRM1 also enriches NPM 
at centrosomes preventing duplication. Mutation of threonine 95 (T95) to the phospho-
mimetic aspartate within the NES of NPM prevents NPM’s association with CRM1 and 
leads to centrosome overduplication (Wang et al. 2005). By contrast, Mukherjee et al. 
provide evidence that NPM’s disassociation with centrosomes is the result of an 
increase in T199 phosphorylation caused by avrainvillamide’s interaction with NPM, 
preventing it’s dephosphorylation by PP1β and not by any direct interaction with PP1β 
itself. Since neither Mukherjee et al. nor Wang et al. report the phosphorylation states 
of T95 or T199 (or any other phosphorylation site for that matter) respectively, it is 
difficult to tell whether there is some kind of interaction between these two (or other) 
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phosphorylation sites and how they both contribute to centrosome regulation. T199 
phosphorylation has only recently been shown to be dependent on another 
phosphorylation site, serine 4 (Ling et al. 2015) so it is clear that more than 10 years 
after the discovery of NPM’s role in centrosome duplication,  there are many 
complexities yet to be illuminated of which the next chapter of this thesis can only begin 
to explore.  
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5 Consequences of increased NPMc phosphorylation 
5.1 Introduction 
The centrosome is a non-membrane bound organelle consisting of two orthogonally 
arranged centrioles surrounded by electron-dense pericentriolar material. As the main 
microtubule-organizing centre of animal cells, it is responsible for nucleating spindle 
poles for the separation of duplicated DNA in mitosis so duplication of DNA and 
centrosome are coupled in most cells, both being triggered by the cyclin-dependant 
kinase (cdk) 2/cyclin (cyc) E complex which is active in mid-late G1 phase of the cell 
cycle (Okuda 2002). Without coordinated centrosome amplification, cells may end up 
with mono- or multi-polar spindle assemblies, causing improper chromosome 
segregation and ploidy, thus contributing to genomic instability (Delattre and Gönczy 
2004).  
Genomic instability has been described as one of the hallmarks of cancer (Hanahan and 
Weinberg 2011) and acute myeloid leukaemia (AML) is no exception with 50-60% of 
cases having an abnormal karyotype. Of those with normal karyotype, 61.7% (Falini et 
al., 2005) heterozygously (Quentmeier et al. 2005) express a mutant form of 
nucleophosmin (NPMc; Falini et al., 2009) that is delocalized to the cytoplasm in 
contrast to the wild-type (wt) which is predominantly localized in the nucleolus (Di 
Fiore 2008). NPM has been implicated as an inhibitor of centrosome duplication. NPM-
/- fibroblasts develop tetraploidy and aneuploidy caused by centrosome 
overamplification (Grisendi et al. 2005) and depletion of NPM in the cytoplasm using 
the nuclear export inhibitor leptomycin B also induces supernumerary centrosomes 
(Shinmura et al., 2005). Despite the fact that NPMc has greater accessibility to the 
centrosome as both localised in the cytoplasm, it still remains a largely untapped topic. 
The previous chapter demonstrated the link between NPM localisation and 
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phosphorylation. This chapter aims to further advance this link with respect to cellular 
proliferation, the means by which malignant cells increase their number, disrupting the 
homeostasis of the body.  
5.2 Results 
5.2.1 Phosphorylation inhibition causes greater G2/M arrest of cells 
with only one centrosome in NPMc-overexpressing cells than 
wtNPM and GFP counterparts 
A cell cycle analysis of the effects of cdk2 inhibition on synchronised cells (Figure 5.1) 
was consistent with previous results on non-synchronised cells (Figure 3.6, upper 
panel): The number of cells in G2/M and S phase increased with a corresponding 
decrease in G0/G1. However, the effect is augmented in synchronised cells as most 
cells are in a similar cell cycle stage and hence respond similarly unlike non-
synchronised cells where the effect may be masked by different cells in different cell 
cycle stages.  
Only in NPMc-overexpressing cells does the number of G2/M phase cells exceed those 
in G0/G1 upon GW8510 treatment (Figure 5.1) indicating that NPMc-overexpressing 
cells are much more dependent than GFP or wtNPM controls on cdk2 activity for 
mitotic progression.  
 
Figure 5.1 Cdk2 inhibition causes G2/M phase arrest 
Cells were synchronized by serum starvation for 72 hours and then released into complete 
media containing GW8510 or the control solvent dimethyl sulfoxide (DMSO) for 24 hours. 
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Statistical significance was calculated using student’s T-test in comparison to DMSO controls. 
* p<0.05. Adapted from Chan and Lim 2015. 
 
To monitor the state of centrosomes during such a cell cycle arrest, cells were fixed and 
stained with the centrosome-specific marker protein γ-tubulin followed by a 
fluorescence-conjugated secondary antibody (Figure 5.3). The visualised centrosomes 
could then be tallied and the number of cells with one, two or more than two 
centrosomes counted.  
Despite the obvious difference in cell cycle response to cdk2 inhibition, centrosome 
numbers did not change significantly for both synchronized and non-synchronized cells 
(Figure 5.3), indicating that the centrosome and DNA replication cycle were decoupled. 
The increase in 4n cells without a concurrent increase in cells with 2 centrosomes upon 
cdk2 inhibition suggests that the DNA has completed its duplication but not the 
centrosome thus preventing mitotic progression causing the accumulation of cells in 
G2/M phase. As NPMc-overexpressing cells have the greatest number of arrested cells, 
this suggests that cells with NPMc have a greater dependency than wtNPM on cdk2 




Figure 5.2 Examples of centrosome staining in HEK293T stable cell lines under control 
(DMSO) or GW8510 treatments. 
Centrosomes appear as distinct red puncta (arrowheads) which can be counted. HEK293T 
stably expressing GFP, GFP-wtNPM (wtNPM) or GFP-NPMc (NPMc) were stained with rabbit 
anti-γ-tubulin followed by anti-rabbit Alexa fluor 568 conjugate. Bar=20μM. DMSO, cells 
treated 0.1% v/v of the solvent dimethyl sulfoxide as control for 24 hours; GW8510, cells 
treated with 5μM of the cdk2 inhibitor for 24 hours; GFP, HEK293T stably overexpressing 
GFP; wtNPM, HEK293T stably overexpressing GFP-wtNPM; NPMc, HEK293T stably 





Figure 5.3 Centrosome numbers do not change significantly upon cdk2 inhibition 
Centrosome numbers in non-synchronized cells (a) and synchronized cells (b). Cells were 
treated with or without 5μM of cdk2 inhibitor GW8510 for 24 hours and then fixed and stained 
for γ-tubulin protein which is specific to centrosomes. 1, cells with 1 centrosome; 2, cells with 
2 centrosomes; >2, cells with 3 or more centrosomes. Results show mean and standard error 
from three independent experiments. Adapted from Chan and Lim 2015. 
5.2.2 Serine 4 is also disparately phosphorylated 
As further evidence that the disparate T199 phosphorylation of NPM is primarily due 
to its localisation with respect to the centrosome, the state of other NPM 
phosphorylation sites was investigated via western blot. Of the other centrosome related 
NPM phosphorylation sites, only serine 4 had a similar discrepancy as T199. Both 
phosphorylation of serine 125 which is associated with NPM homooligomerisation (Xia 
et al. 2013) and threonines 234/237  (T234/7) which are associated with the centrosome 
during mitosis (Cha et al. 2004) did not differ between wtNPM and NPMc (Figure 5.4). 
We propose that as the nuclear envelope breaks down during mitosis, this removes the 
relevancy of NPM’s cellular localisation to the phosphorylation of the mitotic T234/7 
site because all cellular NPM regardless of whether it is wild type or mutant is no longer 
physically separated from the centrosome resulting in similar phosphorylation levels. 
Serine 4 and T199, however, are phosphorylated pre-mitosis (Ling et al. 2015) when 
the nuclear envelope separates wtNPM and the centrosome. In this case, the different 
subcellular locales of wtNPM versus NPMc become relevant in determining the level 




Figure 5.4 Western blot of selected phosphorylation sites 
Pre-mitotic phosphorylation site serine 4 (NPMpS4) also shows similar disparity between 
wtNPM and NPMc but there is no such difference for other centrosome related sites serine 125 
(NPMpS125) or threonines 234 and 237 (NPMpT234/7). G, HEK293T stably overexpressing 
GFP; W, HEK293T stably overexpressing GFP-wtNPM; C, HEK293T stably overexpressing 
GFP-NPMc. 
5.2.3 Alanine-mutated NPMc mimics G2/M phase arrest caused by 
cdk2 inhibition 
To show that G2/M phase arrest was not due to unspecific effects of the drug, site-
directed mutagenesis was used to change T199 or S4 to non-phosphorylatable alanine. 
HEK293T cells were then transfected with either GFP-NPMc or the mutated GFP-
NPMcT199A/S4A and treated with GW8510 before cell cycle analysis using flow 
cytometry. Western blot shows that the T199A mutant is undetectable by the phospho-
T199 antibody (Figure 5.5b) and the localization of the T199A and S4A mutants were 
cytoplasmic showing that the mutation did not affect the localization of GFP-NPMc 
(Figure 5.5a). In addition, T199 phosphorylation of NPMcS4A and S4 phosphorylation 
of NPMcT199A mutant did not differ greatly from the non-mutated NPMc indicating 
that phosphorylation inhibition of either site did not affect phosphorylation of the other 
site. However, inhibition of NPMcT199 phosphorylation by site-directed mutagenesis 
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caused a cell cycle arrest similar to drug treatment indicating that the increase in G2/M 
phase cells is not due to any indirect effect of GW8510 (Figure 5.5c). Transfection of 
NPMcS4A also resulted in a G2/M phase arrest albeit more severe. 
 
Figure 5.5 Alanine-mutated NPMc mimics G2/M phase arrest caused by cdk2 inhibition.  
(a) Light microscope images of HEK293T transfected with GFP-NPMc (NPMc), GFP-NPMc 
with mutated T199A (T199A) or GFP-NPMc with mutated S4A (S4A). All mutants have the 
same subcellular localization (cytoplasm) as NPMc. Bar=100µM. (b) Western blot shows that 
NPMcT199A and NPMcS4A are not detectable by antibody specific for phosphorylated NPM 
(NPMpT199 and NPMpS4, respectively). (c) HEK293T were transfected with GFP-NPMc 
(NPMc), GFP-NPMc with mutated T199A (T199A) or GFP-NPMc with mutated S4A (S4A) 
and treated with GW8510 or the solvent DMSO for 24 hours 24 hours post-transfection. Results 
show mean and standard error from three independent experiments. * p-value < 0.05, ** p-
value < 0.01. Statistical significance was calculated using student’s T-test compared to the 
respective NPMc treatment. G0/G1, cells with 2n DNA content; S, cells synthesizing DNA; 






5.2.4 NPMc-expressing AML cell line is more sensitive to 
dephosphorylation inhibition 
OCI-AML3 (AML3) is the only AML cell line that has so far been found to 
heterozygously express the NPMc mutation (Quentmeier et al. 2005). 
Immunofluorescence staining of NPM in AML3 shows that NPM is cytoplasmically 
localised in contrast with another AML cell line (OCI-AML2) which bears nuclear 
localized wtNPM24 (Figure 5.6a). Western blot of selected centrosome-related 
phosphorylation sites show that while T95, S125 and T234/7 were not disparately 
phosphorylated, the pre-mitotic phosphorylation site S4 had higher phosphorylation in 
AML3 compared to AML2 (Figure 5.6b). This further supports the importance of 
NPM’s accessibility to the centrosome which is restricted by the nuclear envelope in 
pre-mitotic wtNPM-expressing cells. By contrast, we posit that in NPMc-expressing 
AML3, NPMc’s ready access to the centrosome leads to compensatory 
hyperphosphorylation to prevent too much NPM binding to the centrosome which 





Figure 5.6 S4 is likewise hyperphosphorylated in NPMc-expressing cell line OCI-AML3. 
(a) Immunofluorescence co-staining of centrosome marker γ-tubulin (red puncta) and NPM 
(green) show that OCI-AML3 (AML3) has cytoplasmic NPM while OCI-AML2 (AML2) has 
wtNPM which is localised in the nucleus and separated from the centrosome by the nuclear 
envelope. Bar=10μM. (b) Western blot of selected NPM phosphorylation sites. S4 is more 
phosphorylated in AML3 compared to AML2. Other phosphorylation sites are not significantly 
different. Adapted from Chan and Lim 2015. 
 
To see what impact dephosphorylation inhibition would have on NPMc- versus 
wtNPM-expressing cells, AML2/3 were treated with PP1 inhibitors tautomycin and 
calyculin A. Both cell lines responded similarly in a dose-dependent manner to drug 
treatment (Figure 5.7, upper panel): The phosphorylation of T199 increased. 
Furthermore, both drugs induced double strand breaks as evidenced by activated 
H2A.X (Figure 5.7, lower panel, orange line) which becomes phosphorylated on serine 





Figure 5.7 NPM hyperphosphorylation is correlated with genome instability and cell 
death. 
Upper panel, Western blot of NPMpT199 in response to PP1 inhibition by the drugs tautomycin 
and calyculin A for 24 hours. Lower panel, correlation of cell death with DNA damage caused 
by PP1 inhibition. Activated H2A.X was assayed used immunostaining of phosphorylated 
serine 139 on H2A.X and quantifying the subsequent fluorescence using flow cytometry. 
Apoptotic cells were assayed using annexin V and PI staining. Any cell negative for both stains 
was considered live. Cells that were positive for either or both annexin V and PI stains were 
considered apoptotic. Data are representative three independent experiments, averaged. Error 
bars represent standard error. 
 
Despite similar levels of H2A.X activation, AML3 had a higher number of apoptotic 
cells for both control and treated samples. This could be because AML2 and AML3 
have different p53 statuses: the former overexpresses mdm4 which sequesters p53 in 
the cytoplasm as an inactive form (Tan et al. 2014). Therefore p53 is AML3 has greater 




Since 2005 when the NPMc mutation was discovered, there has been a great dearth on 
its impact on centrosome duplication. Only recently has there been some foray into the 
relationship between NPMc phosphorylation and centrosome duplication (Mukherjee 
et al. 2014). Even though Mukherjee et al. show that T199 is affected in treated NPMc+ 
AML, the paper fails to compare the relative levels of phosphorylation in NPMc and 
wtNPM. Furthermore, there is no attempt to evaluate the impact of other 
phosphorylation sites. So while the prospect of nucleoli relocalisation is an exciting 
development, much more work still needs to be done to understand the resulting 
centrosome overduplication of avrainvillamide and leptomycin B (lepB) treatment 
(Wang et al. 2005; Mukherjee et al. 2014).  
It is interesting that phosphorylation of the NES motif (T95) does not differ between 
AML2 and AML3 (Figure 5.6) since phosphorylation of this site abolishes CRM1 
binding which would localise NPM to centrosomes. So T95 phosphorylation could be 
another strategy (in addition to S4 and T199) in which the NPMc+ cell avoids NPM 
inhibition of centrosomes. However, because CRM1 also exports NPM from the 
nucleus into the cytoplasm, T95 phosphorylation would also result in nuclear 
relocalization and the other oncogenic advantages of NPMc (Section 1.5.1) would be 
sacrificed. Therefore, to maintain proliferative advantage, other avenues of dissociating 
NPM away from the centrosome are employed. This is perhaps the reason why T95 
phosphorylation is not disparate between AML3 and AML2.  
Serine 125 is also not disparately phosphorylated. Phosphorylated S125 promotes 
oligomerisation of NPM which supports centrosomal localisation. Mutation of S125 to 
alanine induces centrosome amplification and phosphorylated S125 is only detected at 
centrosomes during G1 when there is one centrosome and not during S or G2 when 
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there are duplicated centrosomes (Xia et al. 2013; Shandilya et al. 2014). Therefore, 
reduced S125 phosphorylation would keep excess NPM away from centrosomes. 
However, this would also reduce oligomerisation and affect NPMc’s ability to pull 
wtNPM out of the nucleus. Again, the phosphorylation of S125, like T95, affects not 
only centrosome regulation but also localisation. Hence, S125 is also not found to be 
instrumental in overcoming NPMc’s centrosome duplication inhibition.  
While the localisation of NPMcS125 and NPMcT95 phosphorylation mutants are yet 
unconfirmed, Figure 5.5 shows that mutation of S4 and T199 do not affect the 
localisation of NPMc. They are therefore more suited to be used to reduce NPM’s 
inhibition of centrosome duplication, allowing mitosis to progress. 
Furthermore, previous studies have indicated that wtNPM T199 phosphorylation is 
dependent on S4 phosphorylation as the S4A mutants have greatly reduced T199 
phosphorylation (Ling et al. 2015). However, the authors did not evaluate the impact of 
a T199A mutant on S4. Figure 5.5b shows that for NPMc, mutation of T199 site has 
little impact on S4 and vice versa. Perhaps the cytoplasmic load of NPMc overrides the 
dependency relationship between S4 and T199. Clearly, more work is needed to 





Figure 5.8 Proposed Model. 
Intensity of yellow increases from left to right to symbolise increasing phosphorylation. Most 
of wtNPM is localised in the nucleus away from the centrosome so only an intermediate amount 
of phosphorylation by Cdk2 is needed to permit centrosome duplication. Too much 
unphosphorylated NPM in the cytoplasm, caused by drug treatment (GW8510) or site-directed 
mutagenesis (T199A), inhibits centrosome duplication and causes cell cycle arrest of cells with 
duplicated DNA (4n arrest). Therefore, extra phosphorylation is needed (yellow lightning). 
Inhibition of the phosphatase (PP1β) increases apoptosis and H2A.X phosphorylation, an 
indicator of DNA double stranded breaks which usually causes cell death by triggering p53. 
5.3.1 NPM and other centrosome regulators 
The evidence in this chapter alludes to the necessity of elevated phosphorylation as a 
compensatory mechanism for NPMc+ cells to permit centrosome duplication. 
Inhibition of this phosphorylation leads to cell cycle arrest (Figure 5.8). However, many 
questions about NPM(c)’s exact role in centrosome duplication remain unanswered. 
For example, Rho-associated kinase (ROCK2) is a downstream effector of NPM and 
its kinase activity is upregulated 5-10 fold following interaction with NPMpT199 (Ma 
et al. 2006; Ling et al. 2015). BRCA2 also interacts with NPM. Abrogation of this 
interaction leads to overamplification of centrosomes leading to multipolar mitosis and 
multinucleated cells (Wang et al. 2011). While the domains of BRCA2 and ROCK2 
that interact with NPM are known (amino acids 639–1,000 and 6-553, respectively), 
the same cannot be said for NPM. Mapping NPM’s interaction region with 
BRCA2/ROCK2 would help deduce the stoichiometry of this interaction and aid in 
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deciphering how increase in cytoplasmic NPM could affect these interactions and 
whether T199 phosphorylation directly affects binding or, instead, induces 
conformational change that changes propensity for BRCA2/ROCK2 interaction. 
BRCA2 itself is responsible for 76% of male and female familial breast cancer (Ford et 
al. 1998) which is commonly found to possess centrosomal abnormalities and genomic 
instability (Guo et al. 2007). Furthermore, there is evidence that benign tumours differ 
significantly in terms of centrosome (dys)regulation from malignant tumours 
(Kronenwett et al. 2005). Therefore, further work would be needed to elucidate exactly 
how NPMc changes the dynamic between ROCK2, BRCA2 and other centrosomal 
regulators. 
BRCA1 is also an interaction partner of NPM and its mutations account for 80% of 
familial breast and ovarian cancers (Couch 2004). BRCA1-dependant ubiquitination of 
γ-tubulin inhibits centrosome duplication (Parvin 2009) and it would be interesting to 
see if NPMc’s ubiquitination status is affected in light of its cytoplasmic localisation. 
Therefore, further studies into NPMc’s centrosomal role benefit not only AML in which 
the mutation is found but the results of such studies could also be valuable for other 
cancers with a predisposition to genomic instability.  
Already, the targeting of NPM in animal models of multiple myeloma (MM) have been 
shown to induce cell death by increasing multipolar spindle in mitosis. NPM was found 
to be the target of a phthalimide derivative, 2-(2,6-diisopropylphenyl)-5-amino-1H-
isoindole-1,3- dione (TC11). MM is inherently gnomically instable and has multiple 
centrosomes but works around this by clustering extra centrosomes into two spindle 
poles during mitosis creating pseudo-normal chromosome separation. NPM 
knockdown or inhibition with TC11 prevents centrosome clustering leading to p53-
independent apoptosis (Shiheido et al. 2012; Matsushita et al. 2015). 
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T199 has also recently been implicated in hepatocellular carcinoma caused by hepatitis 
B virus (HBV).  The HBV protein HBx is correlated with increased T199 
phosphorylation which prevents caspase 3 cleavage of NPM enabling it to execute anti-
apoptotic functions. HBx also interacts directly with NPM in the nucleolus, enhancing 
NPM acetylation and promoting ribosome production (Ahuja et al. 2015). Whether 
NPMc’s other post-translational modifications are affected is also another interesting 




The title of this chapter is somewhat of a misnomer because this thesis is only the 
beginning of exploring NPMc’s relationship with the centrosome.  
In 2000, Hanahan and Weinberg published a generalistic review of cancer in the journal 
Cell that has been cited more than 4000 times entitled “The Hallmarks of Cancer” 
stating six acquired capabilities of malignancy and proposed that these six capabilities 
are common to “most and perhaps all types of human tumors” (Hanahan and Weinberg 
2000). However, in soluble tumours such as AML, the importance of two of these 
capabilities is less relevant compared to solid tumours: Sustained angiogenesis and 
Tissue invasion & metastasis. The remaining four capabilities (self-sufficiency in 
growth signals, insensitivity to antigrowth signals, limitless replicative potential and 
evading apoptosis, Figure 6.1) form the foundation of an imbalance between cell 
division and cell death that characterises the rate of proliferation found in cancer which 
disrupts the homeostasis of the 100 trillion or so cells in the human body (Alberts et al. 
2002). As described in section 1.5, NPMc has been shown to both increase cell 
proliferation and inhibit cell death. This thesis shows that while NPMc can inhibit 
extrinsic cell death (Leong et al. 2010), it’s impact on intrinsic cell death is limited as 
XIAP expression is not increased and caspase 3 and 9 activities are not decreased.  
In 2011, Hanahan and Weinberg published a follow-up article entitled, “Hallmarks of 
cancer: the next generation” (Hanahan and Weinberg 2011). In addition to reviewing 
their previously stated six capabilities more comprehensively, the authors further 
expound four concepts into their model (Figure 6.2). Of these four concepts, it is 





Figure 6.1 The six hallmarks of cancer 





Figure 6.2 Emerging Hallmarks and Enabling Characteristics 
The six capabilities mentioned in the 2000 article are in grey. Additional concepts introduced 
in the 2011 are in colour. Adapted from Hanahan and Weinberg 2011. 
 
Because cancer requires multiple mutations to be manifested, genome instability is the 
means by which these hallmarks of cancer are acquired and this is attested to by the 
correlation between genome instability and poor prognosis (Chan 2011). However, 
genome instability is a double-edged sword: on the one hand, the genetic diversity 
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provided by genome instability is the basis for a Darwinian-like selection that 
encourages the survival of more aggressive cancer cells; on the other hand, too much 
genome instability increases the probability of deleterious mutations that trigger cell 
death and put a stop to cancer progression (Figure 6.3, Cahill et al 1999).  
Cancer cells are thus like the female aphid in winter when conditions are harsher, 
resources are scarce and there is more selection pressure, they switch from asexual 
reproduction to sexual reproduction (Audesirk et al. 2002). Under such circumstances, 
the genetic diversity provided by sexual reproduction becomes advantageous in 
adapting to the changing environment. In summer, aphids take advantage of the 
abundance of food and do away with the hassles of seeking a mate and switch to more 
efficient asexual reproduction, parthenogenetically producing clones of themselves, 
akin to the process of mitosis on a cellular level. For the cancer cell, the source of 
genetic diversity is not sexual reproduction, as in the aphid, but genome instability. On 
this background of increased mutation, the cancer progenitor is able to overcome 
selection barriers such as cell death signals, antigrowth signals and differentiation 
signals.  
The consequences of genome instability are as varied as the cancers they cause but they 
can be roughly divide into two categories: smaller scale DNA lesions such as point 
mutations, deletions and insertions which cannot be detected by fluorescence in-situ 
hybridisation; and larger scale karyotype changes such as chromosomal translocations 
and ploidy which can be caused by faulty double strand break repair and aberrant 
centrosome duplication (Nigg 2002). Again, as in the case of cell death, NPMc is 
selective in the way that it contributes to the genome instability arm of carcinogenesis. 
With 85% of NPMc+ AML being karyotypically normal, this points to a reliance on 
molecular mutations rather than chromosome aberrations as the source of malignant 
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transformation. NPMc is already known to negatively affect two methods of DNA 
repair which would prevent molecular mutations (Fantini et al. 2010; Ziv et al. 2014). 
However, it remains to be determined whether NPMc actually actively contributes to 
molecular mutations, in addition to preventing chromosome aberrations, in a manner 
that potentiates oncogenesis. Considering that NPM interacts with homologous 
recombination proteins BRCA1/2, it would be interesting to see if this repair pathway 
is also affected by NPMc. 
 
Figure 6.3 The "goldilocks" trait of genome instability. 
Reprinted from Trends in cell biology, Vol 9, Daniel P Cahill, Kenneth W Kinzler, Bert 
Vogelstein, Christoph Lengauer, Genetic instability and darwinian selection in tumours, M57-





While the results in this thesis hint at the impact of NPMc on the centrosome, there is 
not enough data to confirm its relationship to genomic instability. In order to ascertain 
this, more centrosomal experiments will need to be done in p53-/- cells. This is because 
in most cells with active p53, centrosome aberrations cause cell death making the study 
of centrosome effectors difficult. This thesis only assays change in centrosome numbers 
once (Figure 5.3) in overexpressing cell line HEK293T as they are easier to grow, 
maintain and manipulate than hematopoietic cell lines AML2/3. For example, 
immunofluorescence staining of AML2/3 requires that they are spun on glass slides 
since they do not adhere to coverslips. The mere centrifugal force of this process causes 
the cell to be somewhat squashed resulting in irregular cell membrane (AML3, GFP 
panel, Figure 5.6) and non-distinct nucleoli (AML2, GFP panel, Figure 5.6). Therefore 
more time and patience is required to optimise such a procedure to reduce cell 
deformities while still maintain enough centrifugal force to stick the cells to the glass 
slide. 
Furthermore, analysis of cyclins (Figure 3.5, Figure 4.2 and Figure 4.3) was done in 
non-synchronised cell and since the levels of cyclins vary according to cell cycle stage, 
it may be necessary to assess whether differential expression of particular cyclins 
facilitate NPMc hyperphosphorylation at G1/S phase as alteration of cyclin expression 
in cultured/tumour cells is not unheard of (Erlandsson et al. 2003; Min et al. 2012). 
In addition, dephosphorylation inhibition was done only using drugs which are non-
specific (Figure 5.7). Tautomycin and calyculin A are both inhibitors of PP1 
(IC50~1nM) but also act against PP2A (Resjö et al. 1999). On top of this, PP1β is 
primarily responsible for NPMpT199 dephosphorylation and not α or γ isoforms but 
the drugs are unable to specifically target PP1β. Ideally, knockdown of PP1β would be 
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the most selective to evaluate the effects of dephosphorylation on centrosome numbers. 
Alternatively, T199 may be mutated to phospho-mimetics aspartate or glutamate as a 
complement to the alanine mutants in Figure 5.5. 
The location of NPM(c) at centrosomes was also not examined thoroughly. Higher 
resolution confocal images would be needed to visualise the movement of NPM(c) and 
phosphorylation mutants at centrosomes in response to lepB treatment. 
Lastly, centrosome abnormalities in animal models of NPMc which already exist (Bolli 
et al. 2010; Cheng et al. 2010) should be evaluated to review the extent of in vivo 
applicability. 
6.2 Future work 
6.2.1 PIP3 signalling 
It seems puzzling that in the 10 years since the discovery of NPMc, its centrosomal 
impact has been neglected until recently. Yet there is another seemingly obvious area 
of NPMc that has yet to be explored: Phosphatidylinositol 3,4,5-triphosphate. 
Phosphatidylinositol 3,4,5-triphosphate or PIP3 is well known secondary messenger in 
the cytoplasm known to activate pro-survival signalling pathways which are often 
mutated in cancer (Carnero et al. 2008). Wild-type NPM is already known to bind PIP3 
in the nucleus and it’s N-terminal 107 amino acids are dispensable for this binding (Ahn 
et al. 2005). Interestingly, NPM’s C-terminal 56 amino acids also bind Akt’s plecstrin 
homology (PH) domain in the nucleoplasm (Lee et al. 2008). Akt is a downstream 
effctor of PIP3 and its interaction with NPM stabilises the latter from caspase 3 
cleavage, preserving its anti-apoptotic role. Nuclear PIP3 enhances NPM-Akt 
interaction but preferentially binds NPM and displaces Akt at higher concentrations 
(Kwon et al. 2010). NPMc could perhaps block the access of PIP3 and prevent the 
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activation of Akt. This would explain the a high level of ERK activation  in NPMc-
expressing cell line OCI-AML3 (Bte Ahmad 2014) as Akt is known to inhibit ERK 
activation by phosphorylating ERK’s upstream kinase Raf (Zimmermann 1999; Guan 
et al. 2000; Moelling et al. 2002; Mendoza et al. 2011). Whether or not NPMc’s 
mutation affects PIP3/Akt binding and dynamics in the cytoplasm remains to be 
ascertained and is an untapped area of study which would yield invaluable information 
about PIP3 signalling in AML. 
6.2.2 Clinical prospects 
Whether T199 or other phosphorylation sites of NPM can or should be targeted remains 
questionable. Since genomic instability is a driver for mutations, the cancer could 
theoretically develop new ways to advance more aggressively. On the other hand, most 
of such mutations are deleterious especially in cells with functional p53. AML3 has 
been shown to not deviate from canonical p53 (Tan et al. 2014) and most AML cases 
also have wild-type p53 (Hu et al. 1992).  
Drugs targeting various aspects of centrosome duplication are already in clinical trials 
(Korzeniewski et al. 2012). It has been shown that cdk inhibitors prevent abnormal 
centrosome duplication but normal cell cycle is not disrupted (Tetsu and McCormick 
2003; Duensing et al. 2004), therefore centrosome duplication inhibitors maybe more 
useful in cancer prevention rather than treatment per se. Even if NPMc’s centrosome 
function is not feasible as a target in cancer treatment, it could still be used as a tool to 
study centrosome regulation.  
6.3 Closing remarks 
While there are many barriers the cancer progenitor must overcome to achieve 
malignancy, the results in this study suggest that for NPMc+AML, the inhibition of 
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centrosome duplication is surpassed by hyperphosphorylation. In the process of 
eliminating XIAP as one of the oncogenic effects of NPMc, the centrosome related 
phosphorylation site T199 was found to be elevated compared to wild-type. This 
hyperphosphorylation was confined to pre-mitotic phosphorylation sites which is 
important as alteration of other phosphorylation sites are related to other cellular 
functions and may negatively affect NPMc’s oncogenic advantages. Furthermore, 
downregulation of T199/S4 phosphorylation induced cell cycle arrest and inhibition of 
dephosphorylation increased double-stranded DNA breaks, a consequence of 
centrosome overamplification. As wtNPM’s centrosomal role has enjoyed many years 





Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P, Sigaux F, Degos 
L, Altieri DC, Dombret H (2000) Expression and prognostic significance of 
survivin in de novo acute myeloid leukaemia. Br J Haematol 111:196–203. 
Adon AM, Zeng X, Harrison MK, Sannem S, Kiyokawa H, Kaldis P, Saavedra HI 
(2010) Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of 
centrosome amplification in p53-null cells. Mol Cell Biol 30:694–710. 
Ahn J-Y, Liu X, Cheng D, Peng J, Chan P-K, Wade PA, Ye K (2005) 
Nucleophosmin/B23, a nuclear PI(3,4,5)P(3) receptor, mediates the antiapoptotic 
actions of NGF by inhibiting CAD. Mol Cell 18:435–45. 
Ahuja R, Kapoor NR, Kumar V (2015) The HBx oncoprotein of hepatitis B virus 
engages nucleophosmin to promote rDNA transcription and cellular proliferation. 
Biochim Biophys Acta - Mol Cell Res 1853:1783–1795. 
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2002) Molecular Biology 
of the Cell, 4th edn.  
Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP, Meani N, 
Diverio D, Bernard L, Tizzoni L, Volorio S, Luzi L, Colombo E, Lo Coco F, 
Mecucci C, Falini B, Pelicci PG (2005) Acute myeloid leukemia bearing 
cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression 
profile characterized by up-regulation of genes involved in stem-cell maintenance. 
Blood 106:899–902. 
Aplan PD (2006) Causes of oncogenic chromosomal translocation. Trends Genet 
22:46–55. 
Arnoldo L, Sgarra R, Chiefari E, Iiritano S, Arcidiacono B, Pegoraro S, Pellarin I, 
Brunetti A, Manfioletti G (2015) A novel mechanism of post-translational 
modulation of HMGA functions by the histone chaperone nucleophosmin. Sci Rep 
5:8552. 
Audesirk T, Audesirk G, Byers B (2002) Biology: Life on Earth, 6th edn. Prentice-Hall, 
Upper Saddle River, New Jersey 
Bagrintseva K, Geisenhof S, Kern R, Eichenlaub S, Reindl C, Ellwart JW, Hiddemann 
W, Spiekermann K (2005) FLT3-ITD-TKD dual mutants associated with AML 
confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression 
of Bcl-x(L). Blood 105:3679–85. 
Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N 
Engl J Med 334:1717–25. 
Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman 
SP, Wu Y-Z, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, 
Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD (2010) Favorable 
Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically 
Normal De Novo Acute Myeloid Leukemia and Associated Gene- and 
MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study. J Clin 
Oncol 28:596–604. 
Belmokhtar CA, Hillion J, Ségal-Bendirdjian E (2001) Staurosporine induces apoptosis 
through both caspase-dependent and caspase-independent mechanisms. Oncogene 
20:3354–62. 
Bhat UG, Jagadeeswaran R, Halasi M, Gartel AL (2011) Nucleophosmin interacts with 
FOXM1 and modulates the level and localization of FOXM1 in human cancer 
cells. J Biol Chem 286:41425–41433. 
 89 
 
Blow JJ, Dutta A (2005) Preventing re-replication of chromosomal DNA. Nat Rev Mol 
Cell Biol 6:476–86. 
Boland CR, Ricciardiello L (1999) How many mutations does it take to make a tumor? 
Proc Natl Acad Sci U S A 96:14675–7. 
Bolli N, De Marco MF, Martelli MP, Bigerna B, Pucciarini A, Rossi R, Mannucci R, 
Manes N, Pettirossi V, Pileri S a, Nicoletti I, Falini B (2009) A dose-dependent 
tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. 
Leuk  Off J Leuk Soc Am Leuk Res Fund, UK 23:501–9. 
Bolli N, Payne EM, Grabher C, Lee J-S, Johnston AB, Falini B, Kanki JP, Look AT 
(2010) Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the 
expansion of hematopoietic cells in zebrafish. Blood 115:3329–40. 
Bonetti P, Davoli T, Sironi C, Amati B, Pelicci PG, Colombo E (2008) Nucleophosmin 
and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J 
Cell Biol 182:19–26. 
Borggrefe T (1998) A B-cell-specific DNA Recombination Complex. J Biol Chem 
273:17025–17035. 
Bornens M (2002) Centrosome composition and microtubule anchoring mechanisms. 
Curr Opin Cell Biol 14:25–34. 
Brady CA, Attardi LD (2010) p53 at a glance. J Cell Sci 123:2527–32. 
Brady SN, Maggi LB, Winkeler CL, Toso EA, Gwinn AS, Pelletier CL, Weber JD 
(2009) Nucleophosmin protein expression level, but not threonine 198 
phosphorylation, is essential in growth and proliferation. Oncogene 28:3209–20. 
Bte Ahmad B (2014) Interaction of receptor interacting protein 1 (rip1) and 
nucleophosmin in the regulation of cell death. National University of Singapore 
Cabrera-Poch N, Pepperkok R, Shima DT (1998) Inheritance of the mammalian Golgi 
apparatus during the cell cycle. Biochim Biophys Acta - Mol Cell Res 1404:139–
151. 
Cahill DP, Kinzler KW, Vogelstein B, Lengauer C (1999) Genetic instability and 
darwinian selection in tumours. Trends Cell Biol 9:M57–60. 
Callen DF (2013) p53 continues to surprise: high levels of p53 can suppress apoptosis. 
Cell Cycle 12:203. 
Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, 
Magaud JP, Guyotat D (1993) High expression of bcl-2 protein in acute myeloid 
leukemia cells is associated with poor response to chemotherapy. Blood 81:3091–
6. 
Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JFM (2008) The 
PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr 
Cancer Drug Targets 8:187–198. 
Carter BZ, Gronda M, Wang Z, Welsh K, Pinilla C, Andreeff M, Schober WD, Nefzi 
A, Pond GR, Mawji IA, Houghten RA, Ostresh J, Brandwein J, Minden MD, 
Schuh AC, Wells RA, Messner H, Chun K, Reed JC, Schimmer AD (2005) Small-
molecule XIAP inhibitors derepress downstream effector caspases and induce 
apoptosis of acute myeloid leukemia cells. Blood 105:4043–50. 
Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC, 
Andreeff M (2008) Triptolide sensitizes AML cells to TRAIL-induced apoptosis 
via decrease of XIAP and p53-mediated increase of DR5. Blood 111:3742–50. 
Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, 
Andreeff M (2006) Triptolide induces caspase-dependent cell death mediated via 
the mitochondrial pathway in leukemic cells. Blood 108:630–7. 
 90 
 
Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W, Dean NM, Steelman 
L, McCubrey J a, Andreeff M (2003) Regulation and targeting of antiapoptotic 
XIAP in acute myeloid leukemia. Leuk  Off J Leuk Soc Am Leuk Res Fund, UK 
17:2081–9. 
Cha H, Hancock C, Dangi S, Maiguel D, Carrier F, Shapiro P (2004) Phosphorylation 
regulates nucleophosmin targeting to the centrosome during mitosis as detected by 
cross-reactive phosphorylation-specific MKK1/MKK2 antibodies. Biochem J 
378:857–65. 
Chae HJ, Kang JS, Byun JO, Han KS, Kim DU, Oh SM, Kim HM, Chae SW, Kim HR 
(2000) Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. 
Pharmacol Res 42:373–81. 
Chan JY (2011) A clinical overview of centrosome amplification in human cancers. Int. 
J. Biol. Sci. 7:1122–1144. 
Chan MYN (2010) Roles of cytoplasmic mutant Nucleophosmin in autophagy and 
mitochondria protection in Acute Myeloid Leukemia. National University of 
Singapore 
Chan N, Lim TM (2015) Cytoplasmic nucleophosmin has elevated T199 
phosphorylation upon which G2/M phase progression is dependent. Sci Rep 
5:11777. 
Chan PK, Chan FY (1995) Nucleophosmin/B23 (NPM) oligomer is a major and stable 
entity in HeLa cells. Biochim Biophys Acta 1262:37–42. 
Chee JLY, Saidin S, Lane DP, Leong SM, Noll JE, Neilsen PM, Phua YT, Gabra H, 
Lim TM (2013) Wild-type and mutant p53 mediate cisplatin resistance through 
interaction and inhibition of active caspase-9. Cell Cycle 12:278–88. 
Chen Z, Indjeian VB, McManus M, Wang L, Dynlacht BD (2002) CP110, a Cell Cycle-
Dependent CDK Substrate, Regulates Centrosome Duplication in Human Cells. 
Dev Cell 3:339–350. 
Cheng K, Sportoletti P, Ito K, Clohessy JG, Teruya-Feldstein J, Kutok JL, Pandolfi PP 
(2010) The cytoplasmic NPM mutant induces myeloproliferation in a transgenic 
mouse model. Blood 115:3341–5. 
Cilloni D, Messa F, Rosso V, Arruga F, Defilippi I, Carturan S, Catalano R, Pautasso 
M, Panuzzo C, Nicoli P, Messa E, Morotti A, Iacobucci I, Martinelli G, Bracco E, 
Saglio G (2008) Increase sensitivity to chemotherapeutical agents and 
cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML 
carrying NPM1 mutations. Leukemia 22:1234–40. 
Colombo E, Bonetti P, Lazzerini Denchi E, Martinelli P, Zamponi R, Marine J-C, Helin 
K, Falini B, Pelicci PG (2005) Nucleophosmin is required for DNA integrity and 
p19Arf protein stability. Mol Cell Biol 25:8874–86. 
Colombo E, Marine J-C, Danovi D, Falini B, Pelicci PG (2002) Nucleophosmin 
regulates the stability and transcriptional activity of p53. Nat Cell Biol 4:529–33. 
Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L, Volorio S, Bernard 
L, Pruneri G, Alcalay M, Pelicci PG (2006) Delocalization and destabilization of 
the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res 
66:3044–50. 
Conacci-Sorrell M, Ngouenet C, Eisenman RN (2010) Myc-nick: a cytoplasmic 
cleavage product of Myc that promotes alpha-tubulin acetylation and cell 
differentiation. Cell 142:480–93. 
Couch FJ (2004) Genetic epidemiology of BRCA1. Cancer Biol Ther 3:509–14. 
 91 
 
Cullen SP, Afonina IS, Donadini R, Lüthi AU, Medema JP, Bird PI, Martin SJ (2009) 
Nucleophosmin is cleaved and inactivated by the cytotoxic granule protease 
granzyme M during natural killer cell-mediated killing. J Biol Chem 284:5137–
47. 
Dai G, Chan KK, Liu S, Hoyt D, Whitman S, Klisovic M, Shen T, Caligiuri MA, Byrd 
J, Grever M, Marcucci G (2005) Cellular uptake and intracellular levels of the bcl-
2 antisense g3139 in cultured cells and treated patients with acute myeloid 
leukemia. Clin Cancer Res 11:2998–3008. 
Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia S V, Wang H-G, Tsang BK, Cheng 
JQ (2004) Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis 
protein (XIAP). J Biol Chem 279:5405–12. 
De Jonge HJM, Huls G, de Bont ESJM (2011) Gene expression profiling in acute 
myeloid leukaemia. Neth J Med 69:167–76. 
De Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, 
Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin 
R, Giralt S (2004) Nonablative versus reduced-intensity conditioning regimens in 
the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: 
dose is relevant for long-term disease control after allogeneic hematopoietic stem 
cell transplantation. Blood 104:865–72. 
Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a 
therapeutic agent for chronic myeloid leukemia. Blood 105:2640–53. 
Delattre M, Gönczy P (2004) The arithmetic of centrosome biogenesis. J Cell Sci 
117:1619–30. 
Den Besten W, Kuo M-L, Williams RT, Sherr CJ (2005) Myeloid leukemia-associated 
nucleophosmin mutants perturb p53-dependent and independent activities of the 
Arf tumor suppressor protein. Cell Cycle 4:1593–8. 
Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC (1999) Cleavage 
of human inhibitor of apoptosis protein XIAP results in fragments with distinct 
specificities for caspases. EMBO J 18:5242–51. 
Dhar SK, Lynn BC, Daosukho C, St  Clair DK (2004) Identification of nucleophosmin 
as an NF-kappaB co-activator for the induction of the human SOD2 gene. J Biol 
Chem 279:28209–19. 
Dhar SK, St Clair DK (2009) Nucleophosmin blocks mitochondrial localization of p53 
and apoptosis. J Biol Chem 284:16409–18. 
Di Fiore PP (2008) Playing both sides: nucleophosmin between tumor suppression and 
oncogenesis. J Cell Biol 182:7–9. 
Di Natale C, Scognamiglio PL, Cascella R, Cecchi C, Russo A, Leone M, Penco A, 
Relini A, Federici L, Di Matteo A, Chiti F, Vitagliano L, Marasco D (2015) 
Nucleophosmin contains amyloidogenic regions that are able to form toxic 
aggregates under physiological conditions.  
Diaz-Corrales FJ, Asanuma M, Miyazaki I, Miyoshi K, Hattori N, Ogawa N (2008) 
Dopamine induces supernumerary centrosomes and subsequent cell death through 
Cdk2 up-regulation in dopaminergic neuronal cells. Neurotox Res 14:295–305. 
Dong F, Guo W, Zhang L, Wu S, Teraishi F, Davis JJ, Fang B (2006) Downregulation 
of XIAP and induction of apoptosis by the synthetic cyclin-dependent kinase 
inhibitor GW8510 in non-small cell lung cancer cells. Cancer Biol Ther 5:165–70. 
Du W, Zhou Y, Pike S, Pang Q (2010) NPM phosphorylation stimulates Cdk1, 




Duensing S, Duensing A, Lee DC, Edwards KM, Piboonniyom S-O, Manuel E, 
Skaltsounis L, Meijer L, Münger K (2004) Cyclin-dependent kinase inhibitor 
indirubin-3’-oxime selectively inhibits human papillomavirus type 16 E7-induced 
numerical centrosome anomalies. Oncogene 23:8206–8215. 
Dunster K, Toh BH, Sentry JW (2002) Early endosomes, late endosomes, and 
lysosomes display distinct partitioning strategies of inheritance with similarities to 
Golgi-derived membranes. Eur J Cell Biol 81:117–24. 
Erlandsson F, Wählby C, Ekholm-Reed S, Hellström A-C, Bengtsson E, Zetterberg A 
(2003) Abnormal expression pattern of cyclin E in tumour cells. Int J Cancer 
104:369–75. 
Estey E (2010) High cytogenetic or molecular genetic risk acute myeloid leukemia. 
Hematology Am Soc Hematol Educ Program 2010:474–80. 
Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van 
Q, Walterscheid M, Kornblau SM (1998) Caspase 2 and caspase 3 protein levels 
as predictors of survival in acute myelogenous leukemia. Blood 92:3090–7. 
Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S, Nicoletti I (2009) Altered 
nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: 
molecular basis and clinical implications. Leuk  Off J Leuk Soc Am Leuk Res 
Fund, UK 23:1731–43. 
Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, Bigerna B, Pasqualucci 
L, Mannucci R, Rosati R, Gorello P, Diverio D, Roti G, Tiacci E, Cazzaniga G, 
Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli MF, Gu W, Mecucci 
C, Nicoletti I (2006) Both carboxy-terminus NES motif and mutated tryptophan(s) 
are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in 
NPMc+ AML. Blood 107:4514–23. 
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, 
Diverio D, Colombo E, Santucci A, others (2005) Cytoplasmic nucleophosmin in 
acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254–
266. 
Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P, Mandelli F, Mecucci C, 
Martelli MF (2007a) Translocations and mutations involving the nucleophosmin 
(NPM1) gene in lymphomas and leukemias. Haematologica 92:519–32. 
Falini B, Nicoletti I, Martelli MF, Mecucci C (2007b) Acute myeloid leukemia carrying 
cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical 
features. Blood 109:874–85. 
Fantini D, Vascotto C, Marasco D, D’Ambrosio C, Romanello M, Vitagliano L, Pedone 
C, Poletto M, Cesaratto L, Quadrifoglio F, Scaloni A, Radicella JP, Tell G (2010) 
Critical lysine residues within the overlooked N-terminal domain of human APE1 
regulate its biological functions. Nucleic Acids Res 38:8239–8256. 
Federici L, Falini B (2013) Nucleophosmin mutations in acute myeloid leukemia: a tale 
of protein unfolding and mislocalization. Protein Sci 22:545–56. 
Fenical W, Jensen PR, Chen XC (2000) Isolation of avrainvillamide from a marine 
fungus off the coast of the Bahamas. Chem Abstr 132:346 709. 
Ferretti R, Palumbo V, Di Savino A, Velasco S, Sbroggiò M, Sportoletti P, Micale L, 
Turco E, Silengo L, Palumbo G, Hirsch E, Teruya-Feldstein J, Bonaccorsi S, 
Pandolfi PP, Gatti M, Tarone G, Brancaccio M (2010) Morgana/chp-1, a ROCK 




Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, 
Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, 
Greally JM, Valk PJM, Löwenberg B, Delwel R, Melnick A (2010) DNA 
methylation signatures identify biologically distinct subtypes in acute myeloid 
leukemia. Cancer Cell 17:13–27. 
Fiorucci S, Mencarelli A, Mannucci R, Distrutti E, Morelli A, del Soldato P, Moncada 
S (2002) NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells 
against apoptosis by modulating mitochondrial function. FASEB J 16:1645–7. 
Fletcher L, Cerniglia GJ, Yen TJ, Muschel RJ (2005) Live cell imaging reveals distinct 
roles in cell cycle regulation for Nek2A and Nek2B. Biochim Biophys Acta 
1744:89–92. 
Fojas de Borja P, Collins NK, Du P, Azizkhan-Clifford J, Mudryj M (2001) Cyclin A-
CDK phosphorylates Sp1 and enhances Sp1-mediated transcription. EMBO J 
20:5737–47. 
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, 
Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck 
S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch 
H, Ponder BAJ, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon 
Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, 
Cannon-Albright LA, Schofield A, Zelada-Hedman M (1998) Genetic 
Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in 
Breast Cancer Families. Am J Hum Genet 62:676–689. 
Fry AM, Mayor T, Meraldi P, Stierhof YD, Tanaka K, Nigg EA (1998) C-Nap1, a novel 
centrosomal coiled-coil protein and candidate substrate of the cell cycle-regulated 
protein kinase Nek2. J Cell Biol 141:1563–74. 
Fukasawa K (2005) Centrosome amplification, chromosome instability and cancer 
development. Cancer Lett 230:6–19. 
Fulda S, Debatin K-M (2006) Extrinsic versus intrinsic apoptosis pathways in 
anticancer chemotherapy. Oncogene 25:4798–811. 
Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, Ishii H, Furukawa Y 
(2005) Methylation silencing of the Apaf-1 gene in acute leukemia. Mol Cancer 
Res 3:325–34. 
Gadad SS, Senapati P, Syed SH, Rajan RE, Shandilya J, Swaminathan V, Chatterjee S, 
Colombo E, Dimitrov S, Pelicci PG, Ranga U, Kundu TK (2011) The 
multifunctional protein nucleophosmin (NPM1) is a human linker histone H1 
chaperone. Biochemistry 50:2780–9. 
Gao H, Jin S, Song Y, Fu M, Wang M, Liu Z, Wu M, Zhan Q (2005) B23 regulates 
GADD45a nuclear translocation and contributes to GADD45a-induced cell cycle 
G2-M arrest. J Biol Chem 280:10988. 
Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, 
Volinia S, Liu C-G, Schnittger S, Haferlach T, Liso A, Diverio D, Mancini M, 
Meloni G, Foa R, Martelli MF, Mecucci C, Croce CM, Falini B (2008) Distinctive 
microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated 
nucleophosmin. Proc Natl Acad Sci U S A 105:3945–50. 
Gébrane-Younès J, Fomproix N, Hernandez-Verdun D (1997) When rDNA 
transcription is arrested during mitosis, UBF is still associated with non-condensed 
rDNA. J Cell Sci 110 ( Pt 1:2429–40. 
 94 
 
Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C (2014) 
Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol 
7:85. 
Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison C, Wheatley K, 
Burnett A, Goldstone A (2001) The predictive value of hierarchical cytogenetic 
classification in older adults with acute myeloid leukemia (AML): analysis of 1065 
patients entered into the United Kingdom Medical Research Council AML11 trial. 
Blood 98:1312–1320. 
Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, Pandolfi PP (2005) 
Role of nucleophosmin in embryonic development and tumorigenesis. Nature 
437:147–53. 
Grisendi S, Mecucci C, Falini B, Pandolfi PP (2006) Nucleophosmin and cancer. Nat 
Rev Cancer 6:493–505. 
Gronda M, Brandwein J, Minden MD, Pond GR, Schuh AC, Wells RA, Messner H, 
Chun K, Schimmer AD (2005) Assessment of the downstream portion of the 
mitochondrial pathway of caspase activation in patients with acute myeloid 
leukemia. Apoptosis 10:1285–94. 
Grummitt CG, Townsley FM, Johnson CM, Warren AJ, Bycroft M (2008) Structural 
consequences of nucleophosmin mutations in acute myeloid leukemia. J Biol 
Chem 283:23326–32. 
Guan KL, Figueroa C, Brtva TR, Zhu T, Taylor J, Barber TD, Vojtek AB (2000) 
Negative regulation of the serine/threonine kinase B-Raf by Akt. J Biol Chem 
275:27354–9. 
Guderian G, Westendorf J, Uldschmid A, Nigg EA (2010) Plk4 trans-
autophosphorylation regulates centriole number by controlling betaTrCP-
mediated degradation. J Cell Sci 123:2163–9. 
Guery L, Benikhlef N, Gautier T, Paul C, Jego G, Dufour E, Jacquel A, Cally R, 
Manoury B, Vanden Berghe T, Vandenabeele P, Droin N, Solary E (2011) Fine-
tuning nucleophosmin in macrophage differentiation and activation. Blood 
118:4694–704. 
Guo H, Gao M, Ma J, Xiao T, Zhao L, Gao Y, Pan Q (2007) Analysis of the cellular 
centrosome in fine-needle aspirations of the breast. Breast Cancer Res 9:R48. 
Gurumurthy M, Tan CH, Ng R, Zeiger L, Lau J, Lee J, Dey A, Philp R, Li Q, Lim TM, 
Price DH, Lane DP, Chao S-H (2008) Nucleophosmin interacts with HEXIM1 and 
regulates RNA polymerase II transcription. J Mol Biol 378:302–17. 
Hamamoto T, Seto H, Beppu T (1983) Leptomycins A and B, new antifungal 
antibiotics. II. Structure elucidation. J Antibiot (Tokyo) 36:646–50. 
Hanahan D, Weinberg R (2011) Hallmarks of cancer: the next generation. Cell 
144:646–74. 
Hanahan D, Weinberg R (2000) The hallmarks of cancer. Cell 100:57–70. 
Hanashiro K, Kanai M, Geng Y, Sicinski P, Fukasawa K (2008) Roles of cyclins A and 
E in induction of centrosome amplification in p53-compromised cells. Oncogene 
27:5288–302. 
Haren L, Remy M-H, Bazin I, Callebaut I, Wright M, Merdes A (2006) NEDD1-
dependent recruitment of the gamma-tubulin ring complex to the centrosome is 
necessary for centriole duplication and spindle assembly. J Cell Biol 172:505–15. 
Haren L, Stearns T, Lüders J (2009) Plk1-dependent recruitment of gamma-tubulin 




Hasegawa H, Yamada Y, Komiyama K, Hayashi M, Ishibashi M, Yoshida T, Sakai T, 
Koyano T, Kam TS, Murata K, Sugahara K, Tsuruda K, Akamatsu N, Tsukasaki 
K, Masuda M, Takasu N, Kamihira S (2006) Dihydroflavonol BB-1, an extract of 
natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells. 
Blood 107:679–688. 
Hasserjian RP (2013) Acute myeloid leukemia: advances in diagnosis and 
classification. Int J Lab Hematol 35:358–66. 
Hayami R, Sato K, Wu W, Nishikawa T, Hiroi J, Ohtani-Kaneko R, Fukuda M, Ohta T 
(2005) Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2. Cancer 
Res 65:6–10. 
Hernandez-Verdun D (2011) Assembly and disassembly of the nucleolus during the 
cell cycle. Nucleus 2:189–94. 
Hernandez-Verdun D, Gautier T (1994) The chromosome periphery during mitosis. 
Bioessays 16:179–85. 
Hernandez-Verdun D, Roussel P, Thiry M, Sirri V, Lafontaine DLJ (2010) The 
nucleolus: structure/function relationship in RNA metabolism. Wiley Interdiscip 
Rev RNA 1:415–31. 
Herrera JE, Savkur R, Olson MO (1995) The ribonuclease activity of nucleolar protein 
B23. Nucleic Acids Res 23:3974–9. 
Himeji D (2002) Characterization of caspase-8L: a novel isoform of caspase-8 that 
behaves as an inhibitor of the caspase cascade. Blood 99:4070–4078. 
Hiramatsu N, Messah C, Han J, LaVail MM, Kaufman RJ, Lin JH (2014) Translational 
and posttranslational regulation of XIAP by eIF2α and ATF4 promotes ER stress-
induced cell death during the unfolded protein response. Mol Biol Cell 25:1411–
20. 
Holland AJ, Fachinetti D, Zhu Q, Bauer M, Verma IM, Nigg EA, Cleveland DW (2012) 
The autoregulated instability of Polo-like kinase 4 limits centrosome duplication 
to once per cell cycle. Genes Dev 26:2684–9. 
Holland AJ, Lan W, Niessen S, Hoover H, Cleveland DW (2010) Polo-like kinase 4 
kinase activity limits centrosome overduplication by autoregulating its own 
stability. J Cell Biol 188:191–8. 
Hu G, Zhang W, Deisseroth AB (1992) P53 gene mutations in acute myelogenous 
leukaemia. Br J Haematol 81:489–494. 
Ibrahim AM, Mansour IM, Wilson MM, Mokhtar DA-H, Helal AM, Al Wakeel HM 
(2012) Study of survivin and X-linked inhibitor of apoptosis protein (XIAP) genes 
in acute myeloid leukemia (AML). Lab Hematol 18:1–10. 
Ishizaki Y, Cheng L, Mudge AW, Raff MC (1995) Programmed cell death by default 
in embryonic cells, fibroblasts, and cancer cells. Mol Biol Cell 6:1443–1458. 
Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, Zhang Y (2003) Tumor 
suppressor ARF degrades B23, a nucleolar protein involved in ribosome 
biogenesis and cell proliferation. Mol Cell 12:1151–64. 
Johansson H, Simonsson S (2010) Core transcription factors, Oct4, Sox2 and Nanog, 
individually form complexes with nucleophosmin (Npm1) to control embryonic 
stem (ES) cell fate determination. Aging (Albany NY) 2:815–22. 
Johansson H, Vizlin-Hodzic D, Simonsson T, Simonsson S (2010) Translationally 
controlled tumor protein interacts with nucleophosmin during mitosis in ES cells. 
Cell Cycle 9:2160–9. 
Johnson K, Liu L, Majdzadeh N, Chavez C, Chin PC, Morrison B, Wang L, Park J, 
Chugh P, Chen H-M, D’Mello SR (2005) Inhibition of neuronal apoptosis by the 
 96 
 
cyclin-dependent kinase inhibitor GW8510: identification of 3’ substituted 
indolones as a scaffold for the development of neuroprotective drugs. J 
Neurochem 93:538–48. 
Jones CE, Busch H, Olson MO (1981) Sequence of a phosphorylation site in nucleolar 
protein B23. Biochim Biophys Acta 667:209–12. 
Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ (2000) Probing spindle assembly 
mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, 
Eg5. J Cell Biol 150:975–88. 
Kasbek C, Yang C-H, Yusof AM, Chapman HM, Winey M, Fisk HA (2007) Preventing 
the degradation of mps1 at centrosomes is sufficient to cause centrosome 
reduplication in human cells. Mol Biol Cell 18:4457–69. 
Kaye FJ (2009) Mutation-associated fusion cancer genes in solid tumors. Mol Cancer 
Ther 8:1399–408. 
Keck JM, Summers MK, Tedesco D, Ekholm-Reed S, Chuang L-C, Jackson PK, Reed 
SI (2007) Cyclin E overexpression impairs progression through mitosis by 
inhibiting APC(Cdh1). J Cell Biol 178:371–85. 
Kitagawa D, Vakonakis I, Olieric N, Hilbert M, Keller D, Olieric V, Bortfeld M, Erat 
MC, Flückiger I, Gönczy P, Steinmetz MO (2011) Structural basis of the 9-fold 
symmetry of centrioles. Cell 144:364–75. 
Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD (1996) The AML1/ETO 
fusion protein activates transcription of BCL-2. Proc Natl Acad Sci U S A 
93:14059–64. 
Kleylein-Sohn J, Westendorf J, Le Clech M, Habedanck R, Stierhof Y-D, Nigg EA 
(2007) Plk4-induced centriole biogenesis in human cells. Dev Cell 13:190–202. 
Kohlmaier G, Loncarek J, Meng X, McEwen BF, Mogensen MM, Spektor A, Dynlacht 
BD, Khodjakov A, Gönczy P (2009) Overly long centrioles and defective cell 
division upon excess of the SAS-4-related protein CPAP. Curr Biol 19:1012–8. 
Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, Jackson CE, Zhang X, 
Champlin R, Estey E, Reed JC, Andreeff M (2002) The anti-apoptotic genes Bcl-
X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-
proliferating leukaemic CD34+ cells. Br J Haematol 118:521–34. 
Korzeniewski N, Hohenfellner M, Duensing S (2012) The centrosome as potential 
target for cancer therapy and prevention. Expert Opin Ther Targets 1–10. 
Krause A, Hoffmann I (2010) Polo-like kinase 2-dependent phosphorylation of 
NPM/B23 on serine 4 triggers centriole duplication. PLoS One 5:e9849. 
Kronenwett U, Huwendiek S, Castro J, Ried T, Auer G (2005) Characterisation of 
breast fine-needle aspiration biopsies by centrosome aberrations and genomic 
instability. Br J Cancer 92:389–395. 
Kuo Y-H, Chen Y-T, Tsai H-P, Chai C-Y, Kwan A-L (2015) Nucleophosmin 
overexpression is associated with poor survival in astrocytoma. APMIS 123:515–
22. 
Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, Meek D, Laiho M (2004) 
Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor 
protein p53 from HDM2-mediated degradation. Cancer Cell 5:465–75. 
Kwon IS, Lee KH, Choi JW, Ahn JY (2010) Pi(3,4,5)P3 regulates the interaction 
between akt and B23 in the nucleus. BMB Rep 43:127–132. 
LaCasse EC (2013) Pulling the plug on a cancer cell by eliminating XIAP with 
AEG35156. Cancer Lett 332:215–24. 
Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358:15–6. 
 97 
 
Lawrence E, Mandato C (2013a) Mitochondrial inheritance is mediated by 
microtubules in mammalian cell division. Commun Integr Biol 6:e27557. 
Lawrence EJ, Mandato CA (2013b) Mitochondria localize to the cleavage furrow in 
mammalian cytokinesis. PLoS One 8:e72886. 
Lee HH, Kim HS, Kang JY, Lee B Il, Ha JY, Yoon HJ, Lim SO, Jung G, Suh SW 
(2007) Crystal structure of human nucleophosmin-core reveals plasticity of the 
pentamer-pentamer interface. Proteins 69:672–8. 
Lee K, Rhee K (2012) Separase-dependent cleavage of pericentrin B is necessary and 
sufficient for centriole disengagement during mitosis. Cell Cycle 11:2476–85. 
Lee SB, Xuan Nguyen TL, Choi JW, Lee K-H, Cho S-W, Liu Z, Ye K, Bae SS, Ahn J-
Y (2008) Nuclear Akt interacts with B23/NPM and protects it from proteolytic 
cleavage, enhancing cell survival. Proc Natl Acad Sci U S A 105:16584–16589. 
Lee T-J, Jung EM, Lee JT, Kim S, Park J-W, Choi KS, Kwon TK (2006) Mithramycin 
A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of 
XIAP gene promoter through Sp1 sites. Mol Cancer Ther 5:2737–46. 
Leong SM, Tan BX, Bte Ahmad B, Yan T, Chee LY, Ang ST, Tay KG, Koh LP, Yeoh 
AEJ, Koay ES-C, Mok Y-K, Lim TM (2010) Mutant nucleophosmin deregulates 
cell death and myeloid differentiation through excessive caspase-6 and -8 
inhibition. Blood 116:3286–96. 
Leung AKL, Gerlich D, Miller G, Lyon C, Lam YW, Lleres D, Daigle N, Zomerdijk J, 
Ellenberg J, Lamond AI (2004) Quantitative kinetic analysis of nucleolar 
breakdown and reassembly during mitosis in live human cells. J Cell Biol 
166:787–800. 
Lew QJ, Chu KL, Chia YL, Cheong N, Chao S-H (2013) HEXIM1, a New Player in 
the p53 Pathway. Cancers (Basel) 5:838–56. 
Lew QJ, Tan CH, Gurumurthy M, Chu KL, Cheong N, Lane DP, Chao S-H (2011) 
NPMc(+) AML cell line shows differential protein expression and lower 
sensitivity to DNA-damaging and p53-inducing anticancer compounds. Cell Cycle 
10:1978–87. 
Lewis NR, Pallis M, Russell NH (2000) Fas receptor-Fas ligand system is independent 
of both CD34 status and chemosensitivity in acute myeloid leukemia. Exp 
Hematol 28:535–542. 
Li J, D’Angiolella V, Seeley ES, Kim S, Kobayashi T, Fu W, Campos EI, Pagano M, 
Dynlacht BD (2013) USP33 regulates centrosome biogenesis via deubiquitination 
of the centriolar protein CP110. Nature 495:255–9. 
Li J, Sejas DP, Rani R, Koretsky T, Bagby GC, Pang Q (2006) Nucleophosmin 
regulates cell cycle progression and stress response in hematopoietic 
stem/progenitor cells. J Biol Chem 281:16536–45. 
Li L, He S, Sun J-M, Davie JR (2004) Gene regulation by Sp1 and Sp3. Biochem cell 
Biol Biochim Biol Cell 82:460–471. 
Lim MJ, Wang X (2006) Nucleophosmin and human cancer. Cancer Detect Prev 
30:481–90. 
Lin CY, Tan BC-M, Liu H, Shih C-J, Chien K-Y, Lin C-L, Yung BY-M (2010) 
Dephosphorylation of nucleophosmin by PP1β facilitates pRB binding and 
consequent E2F1-dependent DNA repair. Mol Biol Cell 21:4409–17. 
Lindström MS (2011) NPM1/B23: A Multifunctional Chaperone in Ribosome 
Biogenesis and Chromatin Remodeling. Biochem Res Int 2011:195209. 
 98 
 
Ling H, Hanashiro K, Luong TH, Benavides L, Fukasawa K (2015) Functional 
Relationship among PLK2, PLK4 and ROCK2 to Induce Centrosome 
Amplification.  
Lischwe MA, Smetana K, Olson MO, Busch H (1979) Proteins C23 and B23 are the 
major nucleolar silver staining proteins. Life Sci 25:701–708. 
Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, Tamai K, Craig CG, 
McBurney MW, Korneluk RG (2001) Identification of XAF1 as an antagonist of 
XIAP anti-Caspase activity. Nat Cell Biol 3:128–33. 
Liu X, Liu D, Qian D, Dai J, An Y, Jiang S, Stanley B, Yang J, Wang B, Liu X, Liu 
DX (2012a) Nucleophosmin (NPM1/B23) interacts with activating transcription 
factor 5 (ATF5) protein and promotes proteasome- and caspase-dependent ATF5 
degradation in hepatocellular carcinoma cells. J Biol Chem 287:19599–609. 
Liu X, Liu Z, Jang S-W, Ma Z, Shinmura K, Kang S, Dong S, Chen J, Fukasawa K, Ye 
K (2007) Sumoylation of nucleophosmin/B23 regulates its subcellular 
localization, mediating cell proliferation and survival. Proc Natl Acad Sci U S A 
104:9679–84. 
Liu Y, Zhang F, Zhang X-F, Qi L-S, Yang L, Guo H, Zhang N (2012b) Expression of 
nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer 
cells. J Biomed Sci 19:53. 
Lo S-J, Fan L-C, Tsai Y-F, Lin K-Y, Huang H-L, Wang T-H, Liu H, Chen T-C, Huang 
S-F, Chang C-J, Lin Y-J, Yung BY-M, Hsieh S-Y (2013) A novel interaction of 
nucleophosmin with BCL2-associated X protein regulating death evasion and drug 
sensitivity in human hepatoma cells. Hepatology 57:1893–905. 
Loo HL (2009) AML-ASSOCIATED NUCLEOPHOSMIN MODULATES THE 
EXPRESSION OF ANTI-APOPTOTIC XIAP. National University of Singapore 
Loubeau G, Boudra R, Maquaire S, Lours-Calet C, Beaudoin C, Verrelle P, Morel L 
(2014) NPM1 silencing reduces tumour growth and MAPK signalling in prostate 
cancer cells. PLoS One 9:e96293. 
Louvet E, Junéra HR, Berthuy I, Hernandez-Verdun D (2006) Compartmentation of the 
nucleolar processing proteins in the granular component is a CK2-driven process. 
Mol Biol Cell 17:2537–46. 
Lu L, Ladinsky MS, Kirchhausen T (2009) Cisternal organization of the endoplasmic 
reticulum during mitosis. Mol Biol Cell 20:3471–80. 
Ma Z, Kanai M, Kawamura K, Kaibuchi K, Ye K, Fukasawa K (2006) Interaction 
between ROCK II and nucleophosmin/B23 in the regulation of centrosome 
duplication. Mol Cell Biol 26:9016–34. 
Maggi LB, Kuchenruether M, Dadey DY a, Schwope RM, Grisendi S, Townsend RR, 
Pandolfi PP, Weber JD (2008) Nucleophosmin serves as a rate-limiting nuclear 
export chaperone for the Mammalian ribosome. Mol Cell Biol 28:7050–65. 
Mahadevan D, Chalasani P, Rensvold D, Kurtin S, Pretzinger C, Jolivet J, Ramanathan 
RK, Von Hoff DD, Weiss GJ (2013) Phase I trial of AEG35156 an antisense 
oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic 
ductal adenocarcinoma. Am J Clin Oncol 36:239–43. 
Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, 
Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, 
Larson RA, Grever MR, Chan KK, Byrd JC (2005) Phase I study of oblimersen 
sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid 




Martelli AM, Nyåkern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L 
(2006) Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical 
implications for human acute myeloid leukemia. Leukemia 20:911–28. 
Matsuo K, Ohsumi K, Iwabuchi M, Kawamata T, Ono Y, Takahashi M (2012) Kendrin 
is a novel substrate for separase involved in the licensing of centriole duplication. 
Curr Biol 22:915–21. 
Matsushita M, Ozaki Y, Hasegawa Y, Terada F, Tabata N, Shiheido H, Yanagawa H, 
Oikawa T, Matsuo K, Du W, Yamada T, Hozumi M, Ichikawa D, Hattori Y (2015) 
A novel phthalimide derivative, TC11, has preclinical effects on high-risk 
myeloma cells and osteoclasts. PLoS One 10:e0116135. 
McCullough S, Lucocq J (2005) Endoplasmic reticulum positioning and partitioning in 
mitotic HeLa cells. J Anat 206:415–25. 
Meder VS, Boeglin M, de Murcia G, Schreiber V (2005) PARP-1 and PARP-2 interact 
with nucleophosmin/B23 and accumulate in transcriptionally active nucleoli. J 
Cell Sci 118:211–22. 
Meloni G, Mancini M, Gianfelici V, Martelli MP, Foa R, Falini B (2009) Late relapse 
of acute myeloid leukemia with mutated NPM1 after eight years: evidence of 
NPM1 mutation stability. Haematologica 94:298–300. 
Mendes-da-Silva P, Moreira A, Duro-da-Costa J, Matias D, Monteiro C (2000) 
Frequent loss of heterozygosity on chromosome 5 in non-small cell lung 
carcinoma. Mol Pathol 53:184–7. 
Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K-mTOR pathways: cross-
talk and compensation. Trends Biochem Sci 36:320–8. 
Min J, Wang X, Tong Y, Li X, Tao D, Hu J, Xie D, Gong J (2012) Expression of cyclins 
in high-density cultured cells and in vivo tumor cells. Cytometry A 81:874–82. 
Minami Y, Yamamoto K, Kiyoi H, Ueda R, Saito H, Naoe T (2003) Different 
antiapoptotic pathways between wild-type and mutated FLT3: insights into 
therapeutic targets in leukemia. Blood 102:2969–75. 
Mitelman F, Johansson B, Mertens F (2007) The impact of translocations and gene 
fusions on cancer causation. Nat Rev Cancer 7:233–45. 
Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M (2002) Regulation of 
Raf-Akt Cross-talk. J Biol Chem 277:31099–106. 
Mohr A, Zwacka RM, Jarmy G, Büneker C, Schrezenmeier H, Döhner K, Beltinger C, 
Wiesneth M, Debatin K-M, Stahnke K (2005) Caspase-8L expression protects 
CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated 
apoptosis. Oncogene 24:2421–9. 
Moore C V (1964) Natural History and Diagnostic Peculiarities of Acute Leukemia. 
CA Cancer J Clin 14:204–9. 
Mukherjee H, Chan K-P, Andresen V, Hanley ML, Gjertsen BT, Myers AG (2014) 
Interactions of the Natural Product (+)-Avrainvillamide with Nucleophosmin and 
Exportin-1 Mediate the Cellular Localization of Nucleophosmin and its AML-
Associated Mutants.  
Mussman JG, Horn HF, Carroll PE, Okuda M, Tarapore P, Donehower LA, Fukasawa 
K (2000) Synergistic induction of centrosome hyperamplification by loss of p53 
and cyclin E overexpression. Oncogene 19:1635–46. 
Nakamura A, Arai H, Fujita N (2009) Centrosomal Aki1 and cohesin function in 
separase-regulated centriole disengagement. J Cell Biol 187:607–14. 
Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa 
K, Shirane M, Tsunematsu R, Tsukiyama T, Ishida N, Kitagawa M, Hatakeyama 
 100 
 
S (2000) Targeted disruption of Skp2 results in accumulation of cyclin E and 
p27(Kip1), polyploidy and centrosome overduplication. EMBO J 19:2069–81. 
Negi SS, Olson MOJ (2006) Effects of interphase and mitotic phosphorylation on the 
mobility and location of nucleolar protein B23. J Cell Sci 119:3676–85. 
Newlands E, Rustin G, Brampton M (1996) Phase I trial of elactocin. Br J Cancer 
74:648–649. 
Nigg EA (2007) Centrosome duplication: of rules and licenses. Trends Cell Biol 
17:215–21. 
Nigg EA (2002) Centrosome aberrations: cause or consequence of cancer progression? 
Nat Rev Cancer 2:815–25. 
Noguera NI, Song MS, Divona M, Catalano G, Calvo KL, García F, Ottone T, 
Florenzano F, Faraoni I, Battistini L, Colombo E, Amadori S, Pandolfi PP, Lo-
Coco F (2013) Nucleophosmin/B26 regulates PTEN through interaction with 
HAUSP in acute myeloid leukemia. Leukemia 27:1037–43. 
Nozawa Y, Van Belzen N, Van Der Made AC, Dinjens WN, Bosman FT (1996) 
Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J 
Pathol 178:48–52. 
Nunnari J, Walter P (1996) Regulation of Organelle Biogenesis. Cell 84:389–394. 
O’Donnell MA, Perez-Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R, Green DR, 
Ting AT (2011) Caspase 8 inhibits programmed necrosis by processing CYLD. 
Nat Cell Biol 13:1437–42. 
Obexer P, Ausserlechner MJ (2014) X-linked inhibitor of apoptosis protein - a critical 
death resistance regulator and therapeutic target for personalized cancer therapy. 
Front Oncol 4:197. 
Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura 
Y, Itoh N, Suda T, Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. 
Nature 364:806–9. 
Okuda M (2002) The role of nucleophosmin in centrosome duplication. Oncogene 
21:6170–4. 
Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, Knudsen ES, 
Hofmann IA, Snyder JD, Bove KE, Fukasawa K (2000) Nucleophosmin/B23 is a 
target of CDK2/cyclin E in centrosome duplication. Cell 103:127–40. 
Okuwaki M (2008) The structure and functions of NPM1/Nucleophsmin/B23, a 
multifunctional nucleolar acidic protein. J Biochem 143:441–8. 
Okuwaki M, Tsujimoto M, Nagata K (2002) The RNA binding activity of a ribosome 
biogenesis factor, nucleophosmin/B23, is modulated by phosphorylation with a 
cell cycle-dependent kinase and by association with its subtype. Mol Biol Cell 
13:2016–30. 
Ortega S, Prieto I, Odajima J, Martín A, Dubus P, Sotillo R, Barbero JL, Malumbres 
M, Barbacid M (2003) Cyclin-dependent kinase 2 is essential for meiosis but not 
for mitotic cell division in mice. Nat Genet 35:25–31. 
Parvin JD (2009) The BRCA1-dependent ubiquitin ligase, gamma-tubulin, and 
centrosomes. Environ Mol Mutagen 50:649–53. 
Paz-Priel I, Cai DH, Wang D, Kowalski J, Blackford A, Liu H, Heckman CA, Gombart 
AF, Koeffler HP, Boxer LM, Friedman AD (2005) CCAAT/enhancer binding 
protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 




Peng J, Zuo Z, Fu B, Oki Y, Tang G, Goswami M, Priyanka P, Muzzafar T, Medeiros 
LJ, Luthra R, Wang SA (2015) Chronic myelomonocytic leukemia with 
nucleophosmin (NPM1) mutation. Eur J Haematol n/a–n/a. 
Peter M, Nakagawa J, Dorée M, Labbé JC, Nigg EA (1990) Identification of major 
nucleolar proteins as candidate mitotic substrates of cdc2 kinase. Cell 60:791–801. 
Pihan G a (2013) Centrosome dysfunction contributes to chromosome instability, 
chromoanagenesis, and genome reprograming in cancer. Front Oncol 3:277. 
Pike AN, Fisk HA (2011) Centriole assembly and the role of Mps1: defensible or 
dispensable? Cell Div 6:9. 
Podhorecka M, Skladanowski A, Bozko P (2010) H2AX Phosphorylation: Its Role in 
DNA Damage Response and Cancer Therapy.  
Poletto M, Lirussi L, Wilson DM, Tell G (2014) Nucleophosmin modulates stability, 
activity, and nucleolar accumulation of base excision repair proteins. Mol Biol 
Cell 25:1641–52. 
Quentmeier H, Martelli MP, Dirks WG, Bolli N, Liso a, Macleod R a F, Nicoletti I, 
Mannucci R, Pucciarini a, Bigerna B, Martelli MF, Mecucci C, Drexler HG, Falini 
B (2005) Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and 
cytoplasmic expression of nucleophosmin. Leuk  Off J Leuk Soc Am Leuk Res 
Fund, UK 19:1760–7. 
Rabouille C, Jokitalo E (2003) Golgi apparatus partitioning during cell division. Mol 
Membr Biol 20:117–27. 
Ramsamooj P, Notario V, Dritschilo A (1995) Modification of nucleolar protein B23 
after exposure to ionizing radiation. Radiat Res 143:158–64. 
Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, 
Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R (2012) 
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 
120:1765–73. 
Rau R, Brown P (2009) Nucleophosmin (NPM1) mutations in adult and childhood 
acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol 
Oncol 27:171–81. 
Reboutier D, Troadec M-B, Cremet J-Y, Fukasawa K, Prigent C (2012) 
Nucleophosmin/B23 activates Aurora A at the centrosome through 
phosphorylation of serine 89. J Cell Biol 197:19–26. 
Resjö S, Oknianska A, Zolnierowicz S, Manganiello V, Degerman E (1999) 
Phosphorylation and activation of phosphodiesterase type 3B (PDE3B) in 
adipocytes in response to serine/threonine phosphatase inhibitors: deactivation of 
PDE3B in vitro by protein phosphatase type 2A. Biochem J 341 ( Pt 3:839–45. 
Röllig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhäuser M, 
Platzbecker U, Stuhlmann R, Schuler U, Soucek S, Kramer M, Mohr B, 
Oelschlaegel U, Stölzel F, Von Bonin M, Wermke M, Wandt H, Ehninger G, 
Schaich M (2010) A novel prognostic model in elderly patients with acute myeloid 
leukemia: results of 909 patients entered into the prospective AML96 trial.  
Ruggero D, Pandolfi PP (2003) Does the ribosome translate cancer? Nat Rev Cancer 
3:179–92. 
Russell JC, Whiting H, Szuflita N, Hossain MA (2008) Nuclear translocation of X-
linked inhibitor of apoptosis (XIAP) determines cell fate after hypoxia ischemia 
in neonatal brain. J Neurochem 106:1357–70. 
 102 
 
Saavedra HI, Maiti B, Timmers C, Altura R, Tokuyama Y, Fukasawa K, Leone G 
(2003) Inactivation of E2F3 results in centrosome amplification. Cancer Cell 
3:333–46. 
Sagawa F, Ibrahim H, Morrison AL, Wilusz CJ, Wilusz J (2011) Nucleophosmin 
deposition during mRNA 3’ end processing influences poly(A) tail length. EMBO 
J 30:3994–4005. 
Sato K, Hayami R, Wu W, Nishikawa T, Nishikawa H, Okuda Y, Ogata H, Fukuda M, 
Ohta T (2004) Nucleophosmin/B23 is a candidate substrate for the BRCA1-
BARD1 ubiquitin ligase. J Biol Chem 279:30919–22. 
Satyanarayana a, Kaldis P (2009) Mammalian cell-cycle regulation: several Cdks, 
numerous cyclins and diverse compensatory mechanisms. Oncogene 28:2925–39. 
Savkur RS, Olson MO (1998) Preferential cleavage in pre-ribosomal RNA byprotein 
B23 endoribonuclease. Nucleic Acids Res 26:4508–15. 
Scaloni F, Federici L, Brunori M, Gianni S (2010) Deciphering the folding transition 
state structure and denatured state properties of nucleophosmin C-terminal 
domain. Proc Natl Acad Sci U S A 107:5447–52. 
Schimmer AD, Herr W, Hänel M, Borthakur G, Frankel A, Horst H-A, Martin S, Kassis 
J, Desjardins P, Seiter K, Fiedler W, Noppeney R, Giagounidis A, Jacob C, Jolivet 
J, Tallman MS, Koschmieder S (2011) Addition of AEG35156 XIAP antisense 
oligonucleotide in reinduction chemotherapy does not improve remission rates in 
patients with primary refractory acute myeloid leukemia in a randomized phase II 
study. Clin Lymphoma Myeloma Leuk 11:433–8. 
Schöckel L, Möckel M, Mayer B, Boos D, Stemmann O (2011) Cleavage of cohesin 
rings coordinates the separation of centrioles and chromatids. Nat Cell Biol 
13:966–72. 
Shandilya J, Senapati P, Dhanasekaran K, Bangalore SS, Kumar M, Hari Kishore A, 
Bhat A, Kodaganur GS, Kundu TK (2014) Phosphorylation of multifunctional 
nucleolar protein nucleophosmin (NPM1) by aurora kinase B is critical for mitotic 
progression. FEBS Lett 588:2198–2205. 
Shields LB, Gerçel-Taylor C, Yashar CM, Wan TC, Katsanis WA, Spinnato JA, Taylor 
DD (1997) Induction of immune responses to ovarian tumor antigens by 
multiparity. J Soc Gynecol Investig 4:298–304. 
Shiheido H, Terada F, Tabata N, Hayakawa I, Matsumura N, Takashima H, Ogawa Y, 
Du W, Yamada T, Shoji M, Sugai T, Doi N, Iijima S, Hattori Y, Yanagawa H 
(2012) A phthalimide derivative that inhibits centrosomal clustering is effective 
on multiple myeloma. PLoS One 7:e38878. 
Shinmura K, Tarapore P, Tokuyama Y, George KR, Fukasawa K (2005) 
Characterization of centrosomal association of nucleophosmin/B23 linked to 
Crm1 activity. FEBS Lett 579:6621–34. 
Skaar TC, Prasad SC, Sharareh S, Lippman ME, Brünner N, Clarke R (1998) Two-
dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen 
regulated protein associated with acquired estrogen-independence in human breast 
cancer cells. J Steroid Biochem Mol Biol 67:391–402. 
Sportoletti P, Grisendi S, Majid SM, Cheng K, Clohessy JG, Viale A, Teruya-Feldstein 
J, Pandolfi PP (2008) Npm1 is a haploinsufficient suppressor of myeloid and 
lymphoid malignancies in the mouse. Blood 111:3859–62. 
Strnad P, Leidel S, Vinogradova T, Euteneuer U, Khodjakov A, Gönczy P (2007) 
Regulated HsSAS-6 levels ensure formation of a single procentriole per centriole 
during the centrosome duplication cycle. Dev Cell 13:203–13. 
 103 
 
Subong EN, Shue MJ, Epstein JI, Briggman J V, Chan PK, Partin AW (1999) 
Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) 
recognizes nucleophosmin/B23. Prostate 39:298–304. 
Suh W-S, Kim YS, Schimmer AD, Kitada S, Minden M, Andreeff M, Suh N, Sporn M, 
Reed JC (2003) Synthetic triterpenoids activate a pathway for apoptosis in AML 
cells involving downregulation of FLIP and sensitization to TRAIL. Leuk  Off J 
Leuk Soc Am Leuk Res Fund, UK 17:2122–2129. 
Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, Chook YM (2013) Nuclear 
export inhibition through covalent conjugation and hydrolysis of Leptomycin B 
by CRM1. Proc Natl Acad Sci U S A 110:1303–8. 
Sung KW, Choi J, Hwang YK, Lee SJ, Kim H-J, Kim JY, Cho EJ, Yoo KH, Koo HH 
(2009) Overexpression of X-linked Inhibitor of Apoptosis Protein (XIAP) is an 
Independent Unfavorable Prognostic Factor in Childhood de Novo Acute Myeloid 
Leukemia. J Korean Med Sci 24:605–613. 
Swaminathan V, Kishore AH, Febitha KK, Kundu TK (2005) Human histone 
chaperone nucleophosmin enhances acetylation-dependent chromatin 
transcription. Mol Cell Biol 25:7534–45. 
Szebeni A, Hingorani K, Negi S, Olson MOJ (2003) Role of protein kinase CK2 
phosphorylation in the molecular chaperone activity of nucleolar protein b23. J 
Biol Chem 278:9107–15. 
Szegezdi E, Cahill S, Meyer M, O’Dwyer M, Samali A (2006) TRAIL sensitisation by 
arsenic trioxide is caspase-8 dependent and involves modulation of death receptor 
components and Akt. Br J Cancer 94:398–406. 
Tago K, Chiocca S, Sherr CJ (2005) Sumoylation induced by the Arf tumor suppressor: 
a p53-independent function. Proc Natl Acad Sci U S A 102:7689–94. 
Takemura M, Sato K, Nishio M, Akiyama T, Umekawa H, Yoshida S (1999) Nucleolar 
protein B23.1 binds to retinoblastoma protein and synergistically stimulates DNA 
polymerase alpha activity. J Biochem 125:904–9. 
Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor 
G, Qui YH, Monks A, Andreeff M, Reed JC (2000) Expression and prognostic 
significance of IAP-family genes in human cancers and myeloid leukemias. Clin 
Cancer Res 6:1796–1803. 
Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F, Karawajew L, 
Ludwig W-D, Wuchter C (2004a) High expression levels of x-linked inhibitor of 
apoptosis protein and survivin correlate with poor overall survival in childhood de 
novo acute myeloid leukemia. Clin Cancer Res 10:3737–44. 
Tamm I, Richter S, Scholz F, Schmelz K, Oltersdorf D, Karawajew L, Schoch C, 
Haferlach T, Ludwig W-D, Wuchter C (2004b) XIAP expression correlates with 
monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J 
5:489–95. 
Tan BX, Khoo KH, Lim TM, Lane DP (2014) High Mdm4 levels suppress p53 activity 
and enhance its half-life in acute myeloid leukaemia. Oncotarget 5:933–43. 
Tan NY, Khachigian LM (2009) Sp1 phosphorylation and its regulation of gene 
transcription. Mol Cell Biol 29:2483–8. 
Tanaka M, Sasaki H, Kino I, Sugimura T, Terada M (1992) Genes preferentially 
expressed in embryo stomach are predominantly expressed in gastric cancer. 
Cancer Res 52:3372–7. 
Tang C-JC, Fu R-H, Wu K-S, Hsu W-B, Tang TK (2009) CPAP is a cell-cycle regulated 
protein that controls centriole length. Nat Cell Biol 11:825–31. 
 104 
 
Tarapore P, Okuda M, Fukasawa K (2002) A mammalian in vitro centriole duplication 
system: evidence for involvement of CDK2/cyclin E and nucleophosmin/B23 in 
centrosome duplication. Cell Cycle 1:75–81. 
Tasdemir E, Chiara Maiuri M, Morselli E, Criollo A, D’Amelio M, Djavaheri-Mergny 
M, Cecconi F, Tavernarakis N, Kroemer G (2008) A dual role of p53 in the control 
of autophagy. Autophagy 4:810–4. 
Testa U, Riccioni R (2007) Deregulation of apoptosis in acute myeloid leukemia. 
Haematologica 92:81–94. 
Tetsu O, McCormick F (2003) Proliferation of cancer cells despite CDK2 inhibition. 
Cancer Cell 3:233–245. 
Tiacci E, Spanhol-Rosseto a, Martelli MP, Pasqualucci L, Quentmeier H, Grossmann 
V, Drexler HG, Falini B (2012) The NPM1 wild-type OCI-AML2 and the NPM1-
mutated OCI-AML3 cell lines carry DNMT3A mutations. Leuk  Off J Leuk Soc 
Am Leuk Res Fund, UK 26:554–7. 
Tokuyama Y, Horn HF, Kawamura K, Tarapore P, Fukasawa K (2001) Specific 
phosphorylation of nucleophosmin on Thr(199) by cyclin-dependent kinase 2-
cyclin E and its role in centrosome duplication. J Biol Chem 276:21529–37. 
Tourneur L, Delluc S, Levy V, Valensi F, Radford-Weiss I, Legrand O, Vargaftig J, 
Boix C, Macintyre EA, Varet B, Chiocchia G, Buzyn A (2004) Absence or low 
expression of fas-associated protein with death domain in acute myeloid leukemia 
cells predicts resistance to chemotherapy and poor outcome. Cancer Res 64:8101–
8108. 
Traver D, Akashi K, Weissman IL, Lagasse E (1998) Mice defective in two apoptosis 
pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 
9:47–57. 
Tschopp J, Irmler M, Thome M (1998) Inhibition of Fas death signals by FLIPs. Curr 
Opin Immunol 10:552–558. 
Tsou M-FB, Stearns T (2006b) Controlling centrosome number: licenses and blocks. 
Curr Opin Cell Biol 18:74–8. 
Tsou M-FB, Stearns T (2006a) Mechanism limiting centrosome duplication to once per 
cell cycle. Nature 442:947–51. 
Tsou M-FB, Wang W-J, George KA, Uryu K, Stearns T, Jallepalli P V (2009) Polo 
kinase and separase regulate the mitotic licensing of centriole duplication in 
human cells. Dev Cell 17:344–54. 
Umekawa H, Sato K, Takemura M, Watanabe Y, Usui S, Takahashi T, Yoshida S, 
Olson MO, Furuichi Y (2001) The carboxyl terminal sequence of nucleolar protein 
B23.1 is important in its DNA polymerase alpha-stimulatory activity. J Biochem 
130:199–205. 
Van Breugel M, Hirono M, Andreeva A, Yanagisawa H, Yamaguchi S, Nakazawa Y, 
Morgner N, Petrovich M, Ebong I-O, Robinson C V, Johnson CM, Veprintsev D, 
Zuber B (2011) Structures of SAS-6 suggest its organization in centrioles. Science 
331:1196–9. 
Van der Eb A (2001) Vaccines and Related Biological Products Advisory Committee 
Meeting. In: USA FDA CTR For Biologics Evaluation and Research. p 81 
Van Hooser AA, Yuh P, Heald R (2005) The perichromosomal layer. Chromosoma 
114:377–88. 
Van Stijn A, van der Pol MA, Kok A, Bontje PM, Roemen GMJM, Beelen RHJ, 
Ossenkoppele GJ, Schuurhuis GJ (2003) Differences between the CD34+ and 
 105 
 
CD34- blast compartments in apoptosis resistance in acute myeloid leukemia. 
Haematologica 88:497–508. 
Vandenabeele P, Declercq W, Van Herreweghe F, Vanden Berghe T (2010) The role 
of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal 3:re4. 
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, 
Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 
revision of the World Health Organization (WHO) classification of myeloid 
neoplasms and acute leukemia: rationale and important changes. Blood 114:937–
51. 
Vascotto C, Lirussi L, Poletto M, Tiribelli M, Damiani D, Fabbro D, Damante G, 
Demple B, Colombo E, Tell G (2014) Functional regulation of the 
apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor 
biology. Oncogene 33:2876–87. 
Wang C, Curtis JE, Minden MD, McCulloch EA (1989) Expression of a retinoic acid 
receptor gene in myeloid leukemia cells. Leuk  Off J Leuk Soc Am Leuk Res Fund, 
UK 3:264–269. 
Wang D, Umekawa H, Olson MO (1993) Expression and subcellular locations of two 
forms of nucleolar protein B23 in rat tissues and cells. Cell Mol Biol Res 39:33–
42. 
Wang G, Gao X, Huang Y, Yao Z, Shi Q, Wu M (2010) Nucleophosmin/B23 inhibits 
Eg5-mediated microtubule depolymerization by inactivating its ATPase activity. 
J Biol Chem 285:19060–7. 
Wang H-F, Takenaka K, Nakanishi A, Miki Y (2011) BRCA2 and nucleophosmin 
coregulate centrosome amplification and form a complex with the Rho effector 
kinase ROCK2. Cancer Res 71:68–77. 
Wang W, Budhu A, Forgues M, Wang XW (2005) Temporal and spatial control of 
nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell 
Biol 7:823–30. 
Wanzel M, Russ AC, Kleine-Kohlbrecher D, Colombo E, Pelicci P-G, Eilers M (2008) 
A ribosomal protein L23-nucleophosmin circuit coordinates Mizl function with 
cell growth. Nat Cell Biol 10:1051–61. 
Warren G, Wickner W (1996) Organelle Inheritance. Cell 84:395–400. 
Welcker M, Clurman BE (2008) FBW7 ubiquitin ligase: a tumour suppressor at the 
crossroads of cell division, growth and differentiation. Nat Rev Cancer 8:83–93. 
Whitehead CM, Rattner JB (1998) Expanding the role of HsEg5 within the mitotic and 
post-mitotic phases of the cell cycle. J Cell Sci 111 ( Pt 1:2551–61. 
Winey M (1991) MPS1 and MPS2: novel yeast genes defining distinct steps of spindle 
pole body duplication. J Cell Biol 114:745–754. 
Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Guo F, Yamaguchi H, Huang M, 
Jove R, Wang HG, Bhalla K (2003) Flavopiridol down-regulates antiapoptotic 
proteins and sensitizes human breast cancer cells to epothilone B-induced 
apoptosis. Cancer Res 63:93–9. 
Wong PS (2010) Heightened XIAP expression by AML-associated mutant NPM is 
mediated by Sp1 but not RIP & JNK signalling pathways and is not involved in 
caspases inhibition. National University of Singapore 
Wuchter C, Krappmann D, Cai Z, Ruppert V, Scheidereit C, Dörken B, Ludwig WD, 
Karawajew L (2001) In vitro susceptibility to TRAIL-induced apoptosis of acute 
leukemia cells in the context of TRAIL receptor gene expression and constitutive 
NF-kappa B activity. Leuk  Off J Leuk Soc Am Leuk Res Fund, UK 15:921–928. 
 106 
 
Wulff JE, Siegrist R, Myers AG (2007) The natural product avrainvillamide binds to 
the oncoprotein nucleophosmin. J Am Chem Soc 129:14444–51. 
Xia X, Liu S, Xiao Z, Zhu F, Song N-Y, Zhou M, Liu B, Shen J, Nagashima K, Veenstra 
TD, Burkett S, Datla M, Willette-Brown J, Shen H, Hu Y (2013) An IKKα-
nucleophosmin axis utilizes inflammatory signaling to promote genome integrity. 
Cell Rep 5:1243–55. 
Xiao J, Zhang Z, Chen GG, Zhang M, Ding Y, Fu J, Li M, Yun J-P (2009) 
Nucleophosmin/B23 interacts with p21WAF1/CIP1 and contributes to its stability. 
Cell Cycle 8:889–95. 
Xiao Q, Ciaassen G, Shi J, Adachi S, Sedivy J, Hann SR (1998) Transactivation-
defective c-MycS retains the ability to regulate proliferation and apoptosis. Genes 
Dev 12:3803–3808. 
Xu Y, Fang F, Dhar SK, Bosch A, St Clair WH, Kasarskis EJ, St Clair DK (2008) 
Mutations in the SOD2 promoter reveal a molecular basis for an activating protein 
2-dependent dysregulation of manganese superoxide dismutase expression in 
cancer cells. Mol Cancer Res 6:1881–93. 
Xu Y, Fang F, Dhar SK, St Clair WH, Kasarskis EJ, St Clair DK (2007) The role of a 
single-stranded nucleotide loop in transcriptional regulation of the human sod2 
gene. J Biol Chem 282:15981–94. 
Yao J, Fu C, Ding X, Guo Z, Zenreski A, Chen Y, Ahmed K, Liao J, Dou Z, Yao X 
(2004) Nek2A kinase regulates the localization of numatrin to centrosome in 
mitosis. FEBS Lett 575:112–8. 
Yao Z, Duan S, Hou D, Wang W, Wang G, Liu Y, Wen L, Wu M (2010) B23 acts as a 
nucleolar stress sensor and promotes cell survival through its dynamic interaction 
with hnRNPU and hnRNPA1. Oncogene 29:1821–34. 
Ye K (2005) Nucleophosmin/B23, a multifunctional protein that can regulate apoptosis. 
Cancer Biol Ther 4:918–23. 
Yi S, Wen L, He J, Wang Y, Zhao F, Zhao J, Zhao Z, Cui G, Chen Y (2015) Deguelin, 
a selective silencer of the NPM1 mutant, potentiates apoptosis and induces 
differentiation in AML cells carrying the NPM1 mutation. Ann Hematol 94:201–
10. 
Yu Y, Maggi LB, Brady SN, Apicelli AJ, Dai M-S, Lu H, Weber JD (2006) 
Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol 
26:3798–809. 
Yun J-P, Miao J, Chen GG, Tian Q-H, Zhang C-Q, Xiang J, Fu J, Lai PBS (2007) 
Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and 
correlation with clinicopathological parameters. Br J Cancer 96:477–84. 
Zaal KJ, Smith CL, Polishchuk RS, Altan N, Cole NB, Ellenberg J, Hirschberg K, 
Presley JF, Roberts TH, Siggia E, Phair RD, Lippincott-Schwartz J (1999) Golgi 
membranes are absorbed into and reemerge from the ER during mitosis. Cell 
99:589–601. 
Zatsepina O V, Rousselet a, Chan PK, Olson MO, Jordan EG, Bornens M (1999) The 
nucleolar phosphoprotein B23 redistributes in part to the spindle poles during 
mitosis. J Cell Sci 112 ( Pt 4:455–66. 
Zhang H, Shi X, Paddon H, Hampong M, Dai W, Pelech S (2004a) B23/nucleophosmin 
serine 4 phosphorylation mediates mitotic functions of polo-like kinase 1. J Biol 
Chem 279:35726–34. 
Zhang X, Hagen J, Muniz VP, Smith T, Coombs GS, Eischen CM, Mackie DI, Roman 
DL, Van Rheeden R, Darbro B, Tompkins VS, Quelle DE (2013) RABL6A, a 
 107 
 
novel RAB-like protein, controls centrosome amplification and chromosome 
instability in primary fibroblasts. PLoS One 8:e80228. 
Zhang XD, Gillespie SK, Hersey P (2004b) Staurosporine induces apoptosis of 
melanoma by both caspase-dependent and -independent apoptotic pathways. Mol 
Cancer Ther 3:187–97. 
Zhang Y, Xiong Y, Yarbrough WG, Hill C, Carolina N (1998) ARF Promotes MDM2 
Degradation and Stabilizes p53 : ARF-INK4a Locus Deletion Impairs Both the Rb 
and p53 Tumor Suppression Pathways. 92:725–734. 
Zhu Y, Shi M, Chen H, Gu J, Zhang J, Shen B, Deng X, Xie J, Zhan X, Peng C (2015) 
NPM1 activates metabolic changes by inhibiting FBP1 while promoting the 
tumorigenicity of pancreatic cancer cells. Oncotarget 
Zimmermann S (1999) Phosphorylation and Regulation of Raf by Akt (Protein Kinase 
B). Science (80- ) 286:1741–1744. 
Ziv O, Zeisel A, Mirlas-Neisberg N, Swain U, Nevo R, Ben-Chetrit N, Martelli MP, 
Rossi R, Schiesser S, Canman CE, Carell T, Geacintov NE, Falini B, Domany E, 
Livneh Z (2014) Identification of novel DNA-damage tolerance genes reveals 
regulation of translesion DNA synthesis by nucleophosmin. Nat Commun 5:5437. 
 
 
